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I. Introduction
1.1 Introduction to Med Dev and Motivations for the Thesis
Med Dev (name changed to protect confidentiality), is a medical device start-up using tissue
engineering and drug delivery techniques to help combat the negative effects associated with secondary
injury. Med Dev's first generation technology is a polymer scaffold that will be inserted into the injury
site immediately post injury during a routine procedure. The scaffold prevents secondary injury (bruising
and scarring) formation by filling the void space left by the injury, promoting cell growth over deleterious
apoptosis (cell death), and slowly degrading away over the course of approximately one month. Med
Dev's second generation technology is a photopolymerizable hydrogel which would function identically
to the first generation, except that it would be injected into the injury rather than surgically inserted.
Med Dev's first and second generation technologies, differ not only in their method of administration,
but also in their manufacture. Commercially available polymers are mechanically processed for scaffold
manufacture, whereas Med Dev must synthesize their own polymers for hydrogel manufacture. Polymer
synthesis requires vast quantities of often toxic solvents to solubilize and later extract the polymer. In the
first generation technology toxic solvent responsibilities lie with Med Dev's suppliers, whereas in the
second generation technology Med Dev is directly responsible for their toxic solvents use. This is not to
say Med Dev should not be aware of their supplier's use of toxic solvents when they are producing
polymers for Med Dev's end-use, but rather to point out that Med Dev is more directly responsible for
toxic solvent use when they produce their own polymers.
In January, as Med Dev's director of operations I applied for a grant which required that I detail how
Med Dev intended to build a green manufacturing facility. Understanding all the toxic solvents involved
in a polymer synthesis, I thought while building a green manufacturing facility was a positive step toward
becoming more environmentally sustainable, why stop there, why not incorporate green thinking into
polymer synthesis process design. A thesis was born.
1.2 Intro to Green Chemistry/Manufacturing
The US EPA defines green chemistry as: "...the design of chemical products and processes that
reduce or eliminate the use or generation of hazardous substances. Green chemistry applies across the life
cycle, including the design, manufacture, and use of a chemical product." ' Green chemistry is essentially
a pollution prevention methodology, resulting in resource conservation, waste reduction, and enhanced
product safety. Companies are beginning to realize that pursuing green chemistry is not only good for the
environment, but also for their bottom line; they are becoming increasingly aware that continued
competitiveness in the allied chemicals industry actually requires the implementation of green chemistry
principles. Paul Anastas and John Warner published what have become the central tenets of green
chemistry in their 1998 book entitled "Green Chemistry: Theory and Practice""; The 12 Principles of
Green Chemistry include:
Figure 1: 12 Principles of Green Chemistry, reproduced from the EPA"'
Historically, limits placed on exposure have been the first line of defense against toxic
substances, green chemistry suggests further minimizing risk by eliminating the use of these
substances altogether wherever possible. The twelve principles of green chemistry speak to
waste reduction, resource conservation, increased reaction and energy efficiencies, the use of
safer alternative solvents, and product stewardship.
Design for the environment is a holistic methodology in which green chemistry is
considered at each stage of a product's life cycle (supply chain, research and development,
manufacturing, and end use) in a quest to minimize the product's impact on the environment.
Green manufacturing, in particular, refers to manufacturing processes that have benefitted from
the implementation of design for the environment and are as a consequence more efficient, safe,
and environmentally friendly.
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The allied chemicals industry has long suffered a very unfavorable reputation, today it ranks
very low in the public's perception, narrowly outranking the nuclear power and tobacco
industries at the bottom of the scale according to attitude and perception studies." This
perception is not without merit, as the allied chemicals industry has been at the center of some of
the twentieth century's most catastrophic manmade disasters, most notably the Bhopal disaster in
Bhopal, India and the Love Canal in Niagra Falls, New York.
The Bhopal disaster occurred at a Union Carbide carbaryl (trade named: Sevin) pesticide
plant on December 3, 1984, when large amounts of water seeped into a tank containing 42 metric
tons of methyl isocynate gas. The methyl isocynate and water reacted, increasing the temperature
within the tank to over 2000 C and causing the pressure to skyrocket. The tank, not designed to
withstand such high temperatures and pressures, began emergency venting thereby releasing
massive quantities of the toxic gas to the environment. The water-methyl isocynate reaction was
further catalyzed by the iron in the corroding non-stainless steel pipelines designed to vent the
tank. In the end, approximately 500,000 people in Bhopal were exposed to the poisonous methyl
isocynate gas (as well as: phosgene, hydrogen cyanide, carbon monoxide, hydrogen chloride,
nitrous oxides, and monomethyl amines). Of the 500,000 exposed, approximately 8,000 people
died in the two weeks immediately following the incident, and another 8,000 people are thought
to have died since due to gas related illnesses, in what has become known as the "world's worst
industrial disaster".' Post mortem investigations of the incident have revealed that poor
maintenance, poor design, storage of methyl isocynate in one large tank rather than several small
tanks, and economic pressures to use methyl isocynate over a safer, though more expensive,
alternative all precipitated the incident. If green chemistry principles and safety had been
considered in the design of the Union Carbide pesticide plant, the disaster could have been
averted.
The Love Canal was named after the developer William T Love, who, in the early 1890's
envisioned building a canal to connect the two levels of the Niagra River. Love's plan to build
the canal never materialized due to financial and preservationist pressures, rather than deter the
developer however, it simply returned him to the drawing board where he devised a plan for a
shipping lane that would reach Lake Ontario without passing Niagra Falls. The developer was
again plagued by financing troubles and had to abandon his project when the canal was only 1
mile long (50 ft wide and 10 to 40 ft deep). The one mile stretch of canal gradually filled with
water, then in the 1920s the municipality of Niagra Falls converted it to a dumping site. In the
1940s Hooker Electrochemical Company (Hooker Chemical Company) began searching for a
dump site for its toxic chemical waste and was granted permission to dump in the Love Canal by
the Niagra Power and Development Company. Hooker drained the canal, lined it with clay and
commenced placing 55 gallon drums of hazardous chemical waste at the site, a practice it
continued until 1952, when the site, containing 21,000 tons of chemicals (caustics, alkalines,
fatty acids, chloronated hydrocarbons), was covered in dirt. In 1953, the Niagra Falls school
board tried to purchase the Love Canal site to construct a school, Hooker Chemical Company
warned the school board against the purchase, but they persisted and the land was developed into
a school; though its original location was moved by 85 ft to avoid being directly atop the landfill.
In 1957, development of the areas directly adjacent to the landfill commenced, the eventual
inhabitants of these developments were unaware of the canals history however. Finally, in 1977,
the Love Canal landfill's protective clay lining was breached by the construction of the La Salle
Expressway and pools of oil and colored liquids began appearing in people's back yards.
Residents complained of smelling strange odors and witnessing substances surface in their back
yards that killed off vegetation. Perhaps most tragic of all Niagra Falls had an inordinately high
number of unexplained illnesses, miscarriages, and mentally retarded children. In fact 56% of
children born in Niagra Falls between 1974 and 1978 had birth defects and 33% of the city's
residents had chromosomal damage compared to 1 % of the general populus." Benzene along
with eleven other known or suspected carcinogens have been found at the site of what has
become known as: "one of the most appalling environmental tragedies in American history""'1
and one of the major impetuses behind the Comprehensive Environmental Response Compensation
and Liability Act (CERCLA) which holds pollution generators accountable for the clean-up of their waste
sites. The Love Canal tragedy also could have been prevented had green chemistry principles been used at
Hooker Chemical Company, certainly waste minimization and solvent substitution could have
ameliorated the environmental burdens of Hooker's landfill.
Designing for the environment by considering green chemistry at every step along a product's
lifecycle, particularly during manufacturing, is a methodology to ensure that such travesties as the Bhopal
disaster and the Love Canal are never repeated. In the Bhopal instance, had safer alternative chemicals or
processes been used and had more care been taken to prevent accidents from happening, the methyl
isocynate tank would never have existed or if it had proper safety precautions surrounding it would have
prevented it from venting. Meanwhile, the Love Canal case, highlights the importance of pollution
prevention, had Hooker Chemical Company reduced the amount and toxicity (through substitution) of
waste they generated the effects on the Niagra Falls community would not have been so vast. Green
chemistry can help the allied chemicals industry regain its lost appeal, by preventing future accidents and
maintaining the health and safety of its employees.
II Why is Green Chemistry Important at this Stage of Med Dev's Development?
Implicit in designing for the environment is a certain robustness; the process is designed right the first
time, in full anticipation of future legislation that might ban the use of a particular solvent or of cost
efficiencies that could be gained by using an alternative reaction route. Designing for the environment not
only allows companies to pre-empt legislation and recognize cost savings, but it also demarcates them as
environmental stewards, helping them gain all the associated accolades with such a distinction.
Designing for the environment is particularly pertinent in the strictly regulated pharmaceutical
industry, where a robust process, that won't suffer from supply chain disruptions or changes in production
methods, is essential. Late stage changes in a pharmaceutical production process can be time consuming
and costly, even without considering the effects of production stoppages:
"It is especially important for the pharmaceutical companies to explore alternative processes early
on, because once a drug and its associated manufacturing process receives FDA approval, it may be cost
prohibitive to make changes and risk having to repeat the regulatory review process."-Vicki Glaser "ii
By designing for the environment a pharmaceutical company mitigates the risk of having to repeat its
regulatory review process, by avoiding toxic substances that might be subject to bans and minimizing
their waste profiles as much as possible.
Today more than ever before, attention is being focused on the environmental performance of
companies and while this performance remains largely voluntary, the future will probably hold much
stricter mandates. Strict mandates on chemical production are already beginning to appear in the form of
legislation and public pressure; the European Union's REACH legislation and Massachusetts Toxics Use
Reduction Act are two examples of stiffening chemicals legislation that will be discussed in this thesis.
Large Pharmaceutical companies have realized the importance of environmental stewardship and
have begun to track their environmental metrics in accordance with the global reporting initiatives (GRI)
G3 guidelinesix, "the world's most widely used sustainability reporting framework."x Pharmaceutical
companies have not stopped at merely tracking their environmental metrics (things like green house gas
emissions, volatile organic compound emissions, hazardous waste generation, and water use), rather they
are actively pursuing green chemistry campaigns which will be outlined in the body of this thesis. As a
signal of this commitment many of the top pharmaceutical companies (Merck, Pfizer, Astra Zeneca,
Glaxo Smith Kline, Schering Plough, Johnson & Johnson, Lilly, and Boehringer Ingelheim) belong to the
American Chemical Society's Green Chemistry Institute's Pharmaceutical Roundtablem. Pharmaceutical
companys' assessment of their environmental performance is not limited to activities that take place
within their confines, they also assess the performance of their suppliers and are making strides to ensure
that pharmaceuticals won't accumulate in the environment after their end use (in an initiative called
pharmaceuticals in the environment). The environmental initiatives many pharmaceutical companies have
taken have helped them decrease production costs, but have also garnered them recognition through
various green chemistry awards and grants, the most notable awards are the EPA's Presidential Green
Chemistry Challenge Awardsx" and the IChemE Sustainable Technology Awards". Most pharmaceutical
companies view green chemistry as one of the major requirements for maintaining competitive advantage;
since green chemistry enables them to realize cost savings while avoiding possible future supply chain
disruptions that could occur due to more stringent legislation.
Med Dev is a burgeoning start-up about to design its first manufacturing facility that will launch it
into human clinical trials. Against a backdrop of increasingly stringent chemical legislation and a
pharmaceutical industry progressively more aware of their environmental performance, that of their
suppliers and their acquisitions, it is logical that Med Dev would investigate greening their manufacturing
processes. This thesis aims to lay out the arguments for adopting green chemistry early, designing for the
environment to stave off the possibility of costly process changes that might be required by stiffer
environmental legislation in the future. Med Dev's manufacturing process and its associated
environmental issues are described, followed by a discussion of current and pending legislation and the
impact these laws might have on Med Dev, then a summary of large pharmaceutical company's
environmental initiatives, and finally a green chemistry approach to Med Dev's manufacturing process is
suggested.
II.1 Med Dev's First Generation Technology
Med Dev's first generation product will be a three dimensionally printed scaffold made of
poly(lactic-co-glycolic acid) (PLGA). Three dimensional printing is an adaptation of ink jet printing
where a liquid 'binder' is printed onto a powder bed rather than ink onto paper. This binder is printed so
that it dissolves and re-solidifies specific areas of powder, in order to construct the desired shape. This
process is iterated in a layer-by-layer fashion until the three-dimensional structure is formed, upon which
the excess unbound powder is carefully removed.
Three Dimensional Printing
For Med Devs' purposes, a three dimensional printer will be used to print an aqueous binder (water)
onto a powder bed of sodium chloride (NaC1) and PLGA. NaCl is used to construct the mold for the
PLGA scaffold. It is fully removed once it has performed its function, leaving only the scaffold with a
precise micro-architecture and customized macro-structural shape tailored to patient requirements.
H.1.1 Materials and Packaging:
PLGA used to construct the scaffold is sourced from Boehringer Ingelheim Pharma GMBH and CO.
KG, Ingelheim, Germany. The particular lactide to glycolide ratio used is 50:50 and is marketed as
RESOMER RG504 or RG504H. This formulation of PLGA has an inherent viscosity of 0.55-0.75, a
glass transition temperature of 45-50 0 C, and an approximate resorption time of 1-2 months. The
fabricated scaffolds will be placed in eppendorf tubes, sealed, and then placed in Tyvek pouches that are
sealed with a heat bar sealer prior to exposure to the electron beam sterilization device.
11.1.2 Process:
PLGA, commercially available in pellet form only, must be milled into a powder for use with three
dimensional printing. Pellets are frozen with liquid nitrogen and then milled with an ultra centrifugal mill,
before they are sieved through screens rated at the appropriate particle size. The PLGA powder is then
blended with the appropriate amount of salt for use in three dimensional printing.
The aqueous binder binds the sodium chloride, forming a printed pattern; whilst entrapping
surrounding water-insoluble PLGA particles. Once the three-dimensional scaffold is completed, it is
moved to a convection oven and heated to 80 *C (the glass transition temperature of PLGA) for 1 hour to
melt the PLGA particles within the salt pre-form. Melted PLGA fills the voids in the salt structure. Upon
cooling, the PLGA solidifies, and then the scaffold is placed in a distilled-deionized water bath to leach
out the sodium chloride.
Legend
- PLGA & sodium chloride
...... water
- salt pre-form
spread powder print layer
Repeat cycle
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PLGA Scaffold Fabrication Process
Once the scaffold has formed and solidified, electron beam sterilization (e-beam sterilization) is
used to sterilize it. During this sterilization process, a linear accelerator generates electrons, which then
excite the electrons within the scaffold producing "secondary energetic species" which include: electrons,
ion pairs, and free radicals. These "secondary energetic species" disrupt the DNA of contaminating
microorganisms and inactivate them affecting full 106 bioburden removal as required by the FDA6". The
scaffolds will be packaged in e-beam compatible, sterile tyvek packaging that will enable them to be
processed and stored prior to emergency room delivery, the appropriate tyvek packaging for this task will
be evaluated. Electron beam sterilization represents the quickest, most efficient, least damaging method of
sterilizing Med Dev's PLGA scaffold.
11.1.3 Environmental Implications of the first generation technology
Med Dev's first generation technology is environmentally innocuous, outside of the use of liquid
nitrogen for freezing the PLGA pellets prior to pulverizing them. The environmental concerns lie with
Med Dev's suppliers and echo those outlined in the discussion of Med Dev's second generation
technology. According to an article in Polymer Degradation and Stability by Dieter Bendix" describing
Boehringer Ingelheim's synthesis of polylactide and its copolymers (poly(lactic-co-glycolic acid)) for
medical applications the process follows these steps:
1.) Lactic acid undergoes direct condensation to form oligo(lactate)
2.) A thermal unzipping reaction with a thermolysis catalyst is performed to yield lactide, a cyclic
diester of lactic acid
3.) The cyclic diesters are then re-crystallized from different solvents to ensure that no oligomers
contaminate the monomer prior to final polymerization.
4.) Ring opening polymerization of the purified cyclic monomers is performed in the presence of
the catalyst tin octoate
5.) Extraction or dissolution/precipitation is finally performed to remove any residual monomers.
The solvents used in recrystalization, extraction, or dissolution and precipitation of the polymer
include: methylene chloride, n-hexane, and diethyl ether. Each of these solvents is hazardous, methylene
chloride and n-hexane are both listed in the US Environmental Protection Agency's (EPA) Toxics
Release Inventory (TRI) chemical list, while diethyl ether is extremely flammable. Thus while Med Dev's
.....- ----.... ......  . .. . .... .... ........ ..... ... . .... ... ....... ...
first generation technology does not have a primary environmental impact, it has a secondary one, which
may be ameliorated through co-operation with its suppliers.
11.2 Med Dev's Second Generation Technology
Med Dev's second generation product will be a photopolymerizable hydrogel. The hydrogel will be
injected into the injury site during a typical surgery and polymerized in situ using a curing light (Curing
Light 2500, 3M Dental Products)."' A hydrogel is comprised of a macromer and a photoinitiator. The
macromer, PEG-co-poly (lactic acid)-diacrylate, has three structural domains: a water soluble central
polymer (PEG), two hydrolytically sensitive oligomeric extenders (ring opened lactide), and two
photopolymerizable termini (acrylate groups). Piantino et al' adapted a two step PEG-co-poly(alpha
hydroxy acid)-diacrylate macromer synthesis technique from Sawhney et alx"' which involves : 1.)
copolymerizing poly(ethylene glycol) with an alpha-hydroxy acid and 2.) functionalizing this copolymer
with acrylate groups to facilitate photopolymerization. Eosin, a photoinitiator, is added to the final
macromer solution and a curing light is used to initiate polymerization. The method discussed herein is
that developed by Piantino et al' with slight variations.
CH3  O CH3
HO-(CH2-CH2-O)I -H + 0 Stannous P HO-(C - C -O)n-(CH 2-CH 2- -(C - c-O)m- H2-ethyl hexanoate
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Poly(ethylene glycol) lactide PEG-co-poly (lactic acid) copolymer
Figure 2: Ring Opening Polymerization. Synthesis of PEG-co-poly(lactic acid) copolymer from
Poly(ethylene glycol) and lactide.
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Figure 3: Acrylation. Synthesis of PEG-co-poly (lactic acid) diacrylate from PEG-co-poly (lactic acid)
copolymer.
11.2.1 Materials and Packaging:
The ring opening polymerization of D,L-lactide with the hydroxyl end groups of poly(ethylene
glycol) is conducted using D,L-lactide and PEG (MW-4000 Da) from Polysciences. PEG was chosen as
the central polymer based on the facts that its nontoxic, its water soluble, it doesn't illicit an immune
response, and it is readily cleared from the body. D,L-lactide was chosen as an extender for the central
PEG molecule because it has very well understood degradation characteristics and its degradation
products (lactate) occur naturally and are easily metabolized. The transesterification catalyst for this ring
opening reaction, stannous 2-ethyl hexanoate, is sourced from Sigma. The acrylation step is conducted
using acryloyl chloride and triethylamine from Sigma. Acrylates were chosen as the end groups for their
ability to undergo rapid photopolymerization with the appropriate initiator (eosin). The degradation
products of acrylates, oligo(acrylic acid) with a degree of polymerization of 2 or 3, are relatively
innocuous as they are both water soluble and nontoxic. For the photopolymerization step, both eosin and
PBS were purchase from Aldrich. All reagents used for dissolution or precipitation (notably: diethyl ether,
methylene chloride, and hexane) are reagent grade and were purchased from Aldrich. A curing light
(Curing Light 2500) is used to initiate polymerization and is sourced from 3M Dental Products.
11.2.2 Process:
1. Synthesis of PEG-co-poly(lactic acid) copolymers
Dry PEG 4k, D,L-lactide, and stannous 2-ethyl hexanoate are all charged into a stainless steel,
pressurizable/vacuum compatible jacketed reactor under nitrogen. The jacketed reactor is used to tightly
control reaction conditions as the reaction mixture is stirred under vacuum at 2000C for four hours and
160 0C for 2 hours, prior to being cooled to room temperature. The resultant polymer is dissolved in
methylene chloride, then precipitated with diethyl ether before being filtered through a large Bruckner
funnel. Once filtration is complete, the filter cake is removed from the funnel and placed in a vacuum
oven to dry.
2. Synthesis of PEG-co-poly(lactic acid) diacrylate macromers
Once the PEG-co-poly(lactic acid) copolymer is dry, it is dissolved in methylene chloride and
placed in a stainless steel jacketed reactor. Then triethylamine and acryloyl chloride dissolved in
methylene chloride are added to the copolymer solution and the reaction is allowed to proceed for 36
hours. Once the reaction is complete, the macromer solution is diafiltered to remove triethanolamine
hydrochloride. Then the macromer is poured into a large excess of diethyl ether to initiate precipitation.
The resultant solution (and precipitate) are filtered through a large Bruckner funnel and the resultant
solids are redissolved in methylene chloride to be precipitated again with hexane. The hexane precipitants
are filtered through a Bruckner funnel and allowed to vacuum dry at 700C, prior to being dissolved in
phosphate buffered saline (PBS). The PBS-macromer solution is then diafiltered to remove all possible
contaminants. At the close of the diafiltration, the macromer solution is concentrated, frozen, and then
lyophilized. The lyophilized product can be reconstituted in PBS and can be investigated for purity using
proton NMR, Infrared spectrophotometry, and a gas chromatograph (each of which will detect excess
reagents/solvents that were not removed by the purification procedures). Once the purity of the macromer
is established it can be combined with the photoinitiator, eosin (0.02%) and triethanolamine, then the
entire hydrogel is filtered through a 0.2 Lm filter to sterilize it for use. The solution will not polymerize
unless the photoinitiator is activated with the curing light, and this activation process will be carried out in
situ.
11.2.3 Environmental Implications of the Second Generation Technology
Med Dev's second generation technology requires the use of vast amounts of toxic solvents such as
dichloromethane, hexane, and diethyl ether. Dichloromethane is used to dissolve the polymer prior to its
reaction with acryloyl chloride, while hexane and diethyl ether are used to affect polymer extraction once
the reaction is complete. Dichloromethane, hexane, and diethyl ether are health as well as a flammability
hazards. Extensive solvent use creates risks for employees directly exposed to the solvents, and the
environment (both during processing and final disposal). Solvents are relatively costly as well, thus steps
should be taken to replace or eliminate toxic solvents wherever possible.
Another area of possible concern in Med Dev's synthesis of its second generation technology, is the
use of stannous 2-ethyl hexanoate as a ring opening catalyst, as studies have demonstrated that the
catalyst is a possible neurodegenerative agent. Substitution of this catalyst, in addition to the solvents
above, should be explored.
III What are the Hazards Associated With the Materials Med Dev Uses?
The hazardous materials Med Dev uses in the synthesis of its second generation technology include:
n-hexane, dichloromethane, diethyl ether, and stannous 2-ethylhexanoate. The exact hazards,
flammability and possible adverse health effects, associated with each chemical are expanded upon here.
Each chemical's use guidelines or limitations are also described.
III.1 n-Hexane
n-Hexane, C6H14 , (CAS No. 110-54-3) is used to effect precipitation of the PEG-co-poly(lactic
acid) diacrylate macromers during hydrogel synthesis.
Flammability n-hexane is a colorless liquid with a boiling point of 690 C and a flash point of -23"C.
The term flash point is used to describe the temperature above which a flammable liquid can form an
ignitable mixture with air, with a flash point of-230C n-hexane is extremely flammable. Lower and upper
explosion limits of a material give the lowest and highest concentration a material required to support its
combustion in air, for hexane its lower explosion limit (lel) is 1.2 (% by volume), and its upper explosion
limit (uel) is 7.7 (% by volume).
Possible Adverse Health Effects In addition to its flammability, n-hexane is harmful or fatal if
swallowed, harmful if inhaled, and causes irritation to the skin, eyes, and respiratory tract. Furthermore,
n-hexane may impair fertility, may cause depression of the central nervous system (CNS), and may cause
serious health effects after prolonged exposure. The MSDS sheet from J.T. Baker"" elaborates on some
of the side effects resulting from inhalation, ingestion, skin and eye contact, as well as chronic exposure.
Inhalation of n-hexane may irritate the respiratory tract, while over exposure may result in lightheadness,
nausea, headache, blurred vision, and extreme exposure may result in muscle weakness, numbness in the
extremities, unconsciousness, and even death. Ingestion may cause abdominal pain and/or nausea, the
ingestion case becomes more dire if n-hexane is aspirated into the lungs where it may cause serious lung
damage. Skin and eye contact both cause irritation and redness. Chronic skin exposure may de-fat the skin
and result in dermatitis; while chronic inhalation exposure may create peripheral or central nervous
system effects.
Use Guidelines and Limitations Lethal dose 50 (LD50) is a term used to describe the dose of a
substance at which 50% of exposed specimens will die, the LD50 for oral ingestion by rats is 28,700
mg/kg. Lethal concentration 50 (LC50) is the concentration of a substance at which 50% of exposed
specimens will die, the LC50 for inhalation by rats is 48,000 ppm/4hrs.
The permissible exposure limits (PEL) legally limit the chemical substance concentration an
employee may be exposed to in the United States and are determined by the Occupational Safety and
Health Administration (OSHA). The PEL for n-hexane is given in the regulations (Standards-29CFR
1910.1000 Table Z1) as an 8 hour time weighted average of 500 ppm'.
The US Food and Drug Administration (FDA) has issued a Guidance for Industry on permissible
residual solvent levels in drug products called "QC3 Impurities: Residual Solvents"". Manufacturing
techniques only effect the partial removal of solvents, residual solvents are those solvents which remain,
un-removed, in the final pharmaceutical product. The FDA prescribes a "permitted daily exposure" (PDE)
which represents the pharmaceutically acceptable residual solvent intake. In establishing PDEs the FDA
groups solvents into 3 classes: class 1 (solvents to be avoided) include "known human carcinogens,
strongly suspected human carcinogens, and environmental hazards", class 2 (solvents to be limited)
include "nongenotoxic animal carcinogens, possible causative agents of other irreversible toxicities, and
solvents suspected of significant but reversible effects", and class 3 (solvents w/low toxic potential)
include those with "low toxic effects on man"'. Hexane is a class 2 solvent according to the FDA
classification and has a PDE of 2.9 mg/day (or, in terms of concentration, 290 ppm). In addition, hexane's
use as a food additive is also regulated by the FDA. Residual hexane concentrations should not exceed: 25
ppm in spice oleoresins (21CFR 173.270), 2.2% in hops extract (21CFR 173.270), 25 ppm in modified
hop extract for beer (21CFR 172.560), or 5 ppm in fish protein isolates (21CFR 172.340).
Hexane is classified as a hazardous air pollutant under section 112 of the US EPA's Clean Air Act"
Major sources of HAP, those that emit 20,000 lbs of a HAP/yr must implement the maximum achievable
control technology (MACT), while small HAP sources, those that emit 2,000 lbs of a HAP/year must
implement generally available control technology (GACT).
111.2 Dichloromethane
Dichloromethane, CH 2C12, (CAS No. 75-09-2) is used to dissolve the PEG-co-poly(lactic acid)
copolymers and other reactants during the PEG-co-poly(lactic acid) diacrylate macromer synthesis step in
Med Dev's hydrogel synthesis.
Flammability Dichloromethane is not a significant flammability risk as it must be heated before it
may combust. The lower and upper explosion limits for dichloromethane are 12 (% by volume) and 19 (%
by volume) ""' respectively.
Possible Adverse Health Effects Dichloromethane is classified as a Carcinogenic, Mutagenic, and
Reproductive Toxin (CMR) category 3 in the European Union, meaning it has probable CMR
characteristics but they have not been proven definitively yet. The US Environmental Protection Agency
(EPA), under the 1986 Guidelines for Carcinogenic Risk Assessment, list dichloromethane as category
B2, a "probable human carcinogen". The International Agency for Research on Cancer (IARC), lists
dichloromethane as category 2B, "possibly carcinogenic to humans", while OSHA lists it as a "potential
human carcinogen"x. Dichloromethane exposure has been implicated in an increased incidence of lung
and liver cancers in laboratory tests performed in mice, however similar exposures have not increased
these cancer incidences in hamsters or rats v. The metabolic pathways used by rats, hamsters, and
humans metabolize dichloromethane to a lesser extent than do those responsible for tumor formation in
rats, and it is therefore unlikely that dichloromethane will promote cancer in humans. Dichloromethane is
a skin and eye irritant. Vapor over exposure may cause depression of the central nervous system
(anesthesia) and may irritate the skin, eyes, mucuous membranes, and respiratory tract. Within the body,
dichloromethane is metabolized to carbon monoxide and raises levels of carboxyhaemoglobin in the
blood stream. The carboxyhaemoglobin concentrations in the blood resulting from dichloromethane
inhalation remain higher, for a longer period of time than those resulting from inhalation of carbon
monoxide. In people with coronary artery disease, carbon monoxide poisoning is particularly serious,
where only marginal increases in carboxyhaemoglobin may result in ischaemia. x
Use Guidelines and Limitations The oral LD50 (rat) for dichloromethane is 1600 mg/kg, while the
inhalation LC50 (rat) is 52 g/m3.
The permissible exposure limit (PEL) prescribed by OSHA for dichloromethane, based on an eight
hour time weighted average, is 25 ppm v.
Dichloromethane is a class 2 solvent according to the FDA classification and has a PDE of 6.0
mg/day (or, in terms of concentration, 600 ppm)x. Due to its potential role as an animal carcinogen and
the potential threats it poses to human health, the use of dichloromethane in cosmetics products is
prohibited x i". In addition, the use of dichloromethane as a food additive is regulated by the FDA, residual
dichloromethane concentrations should not exceed: <30 ppm in spice oleoresins (21CFR 173.255), <10
ppm in decaffeinated roasted coffee and decaffeinated soluble (instant) coffee, <2.2% in hop extract, and
<5 ppm in modified hop extract for beer (21CFR 172.560)"'.
The US EPA has classified dichloromethane as a hazardous air pollutant (HAP) under section 112
of the Clean Air Actx. In 2007 the EPA moved to prohibit the use of dichloromethane in foam adhesives,
while in 2008 the EPA moved to require dichloromethane containing paint strippers to implement
management practices that would reduce solvent evaporation.
111.3 Diethyl ether
Diethyl ether, C4H100, (CAS No. 60-29-7) is used as an extraction agent in the PEG-co-poly(lactic
acid) diacrylate macromer synthesis portion of Med Dev's hydrogel production.
Flammability Diethyl ether is extremely flammable in the presence of open flames or heat, while it is
flammable in the presence of oxidizing agents and acids. Its auto ignition temperature is 180
0 C and its
flash point is -450 C. Diethyl ether ignites or otherwise creates a violent reaction on contact with halogens,
interhalogens, oxidants, sulfur, and sulfur compounds. In addition, diethyl ether tends to form explosive
peroxides upon exposure to light and air. The upper and lower flammability limits for diethyl ether are
1.9% and 36% respectively.
Possible Adverse Health Effects Diethyl ether is a skin and eye irritant, and may cause reversible eye
injury on contact. In addition, diethyl ether is rapidly adsorbed by the lungs upon inhalation and may
result in excitement, drowsiness, headache, nausea, vomiting, increased respiration rate, decreased
pulse/temperature, irregular respiration, coughing, bronchodilation, increased heart rate, excessive
salvation, muscle relaxation, anesthetic affects, kidney irritation/injury, and temporarily abnormal liver
function. Diethyl ether ingestion may result in gastrointestinal tract irritation accompanied by nausea and
vomiting.
Use Guidelines and Limitations The oral LD50 (rat) for diethyl ether is 1215 mg/kg, while the
inhalation LC50 (rat) is 73,000 ppm over 2 hours. OSHA's PEL for diethyl ether on an 8 hour time
weighted average basis is 400 ppm. Diethyl ether is a class 3 solvent according to the FDA classification
and has a PDE of 50 mg/day (or, in terms of concentration, 5000 ppm)x.
III.4 Summary of Hazardous Solvents
LD50
Chemical CAS Boiling Flash LEL UEL (rat, LCS0 OSHA PDE
formula No. point point Ingestion) (rat,Inhalation) PEL
u-au.ha C6H4 110-54-3 690 C -230 C 1.2% 7.7% 28,700 mg/kg ppm/4hrs ppm 290 ppm
Dichloromethane CH2C12  75-09-2 40
0 C None 12% 19% 1,600 mg/kg 52 g/mh 25 6.0 mg/kgWpm 600 ppm
Diethyl ether CioO 60-29-7 34.6
0 C -45C 1.9%. 36% 1,215 mg/kg 50
UEL, LEL: upper, lower explosive limits, lowest and highest concentrations supportive of combustion in air
LD50, LC50: lethal dose (inhalation) or concentration (ingestion) that will kill 50% of exposed specimens
OSHA PEL: permissible exposure limit, legal limit on the concentration of a substance an employee may be
exposed to on an 8hr time weighted average
FDA PDE: permitted daily exposure, pharmaceutically acceptable residual solvent intake
Table 1: Summary of Hazardous Solvents. Summary of key characteristics and limits for each of the
chemicals used in Med Dev's synthesis.
mII.5 Stannous 2-ethylhexanoate
In addition to toxic solvents, Med Dev's hydrogel synthesis route utilizes a catalyst, stannous 2-
ethylhexanoate (also known as stannous octoate, C16H300 4Sn, CAS No. 301-10-0) that may have
neurodegenerative properties. Today, stannous 2-ethylhexanoate is widely used as a catalyst in ring
opening polymerization of poly(lactic acid) and its co-polymers and is FDA approved as a food
additivexm . The toxicity of stannous 2-ethylhexanoate has been investigated both in vivo and in vitro in
conjunction with its use as a food additive, these studies however, surmise the toxicity profile of stannous
2-ethylhexanoate from its dissociation products (stannous 2-ethylhexanoate is completely dissociated at
the pH of the digestive tract (pH 1.2)) stannous and 2-ethylhexanoic acidxm . The acceptable daily intake
(ADI) of 2-ethylhexanoic acid is 0.5 mg/kg BW/day, while for tin the provisional tolerable weekly intake
(PTWI) is 14 mg/kg BW/week (or 2 mg/kg BW/day)"xx.
Very little is known about stannous 2-ethylhexanoate's toxicological profile today. Worried about
the safety profile of medical devices, produced with stannous 2-ethylhexanoate, directed for use in the
brain or central nervous system where they may break the blood-brain barrier, Yamada et al" launched
an exploration of the effects of stannous 2-ethylhexanoate on the central nervous system. Yamada et al
investigated both the in vitro cell viability of normal human astrocytes (NHA) in response to various
concentrations of stannous 2-ethylhexanoate, and the in vivo neurotransmitter and behavioral effects on
rat brains directly injected with stannous 2-ethylhexanoate.
The effects of stannous 2-ethylhexanoate on NHAs were investigated using an Astrocyte Microtiter
Terazolium Assay in which 1 x 104 NHAs were cultured for a week with 2.5, 5, or 10 gtg/mL of stannous
2-ethylhexanoate. After incubating for one week with the stannous 2-ethylhexanoate, the culture media
was replaced, substituted by fresh media, TetraColor One reagent was added to each astrocyte sample and
the samples allowed to sit for two hours prior to reading the absorbance at 450/360 nm. The viability of
normal human astrocytes exposed to 2.5 and 5 jig/mL of stannous 2-ethylhexanoate marginally decreased
(a decrease of 10% and 20% compared to the control, respectively), while the decrease in viability
witnessed for NHAs exposed to 10 jg/mL of stannous 2-ethylhexanoate was significant (80% compared
to the control), as shown in figure 4.
Effect of Stannous 2-ethylhexanoate on Normal Human Astrocytes
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Figure 4: Summary of the effect of various stannous 2-ethylhexanoate concentrations on viability of
normal human astrocytes. From this plot, it is clear that cells treated with 10 jg/mL of
stannous 2-ethylhexanoate are only 20% as viable as those untreated, or alternatively, NHAs
treated with 10 ttg/mL of stannous 2-ethylhexanoate demonstrate an 80% decrease in viability
compared to those untreated. Adapted from Yamada et al.
Decreased viability in normal human astrocytes in response to incubation with stannous 2-ethylhexanoate
suggests that the mitochondrial activity in these cells was suppressed. Suppression of mitochondrial
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~
activity decreases adenosine triphosphate (ATP) production within the cell, thereby disrupting important
processes of energy storage/transport as well as CNS signaling. Yamada et al contest that the decreased
mitochondrial activity witnessed in response to incubation with stannous 2-ethylhexanoate indicates that
the catalyst is cytotoxic to cells in the central nervous system.
Stannous 2-ethylhexanoate was injected intra-cerebrally at a concentration of 6.28 mg/kg BW
(corresponding to 2 mg/kg BW tin (the ADI of tin)). Open field tests were performed on the rats 1, 7, and
30 days post injection to determine the effect stannous 2-ethylhexanoate had on their motor activities
(total locomotion distance, average locomotion speed, number of sections crossed, and beginning
latency). In field studies, the total locomotion distance and the average locomotion speed of the rats
injected with stannous 2-ethylhexanoate decreased and beginning latency increased 1 day post injection.
Seven days post injection there were no differences in the field study test results of the injected and the
control rats. Thirty days post injection, the total locomotion distance and average locomotion speed of the
rats injected with stannous 2-ethylhexanoate increased, while their beginning latency decreased. Open
field tests typically indicate decreased locomotion distance on repeated testing, and Yamada et al point to
the fact that the rats increased their locomotion distance thirty days post injection as evidence of possible
chronic neurotoxicity.
After 30 days the rats were sacrificed and their brain tissue were processed so that
neurotransmitters could be detected using an HPLC fitted with a reverse phase column and an
electrochemical detector. The neurotransmitters measured included dopamine (DA), serotonin (5-HT),
and norepinephrine (NE). Dopamine metabolites, 3,4-dihydroxyphenyl-acetic acid (DOPAC) and
homovanillic acid (HVA), and serotonin metabolites, 5-hydroxyindole-3-methoxyphenylacetic acid
(5HIAA) were also measured. Neurotransmission of dopamine (DA) promotes ambulation and decreases
anxiety in rats. Depression may result from dysfunctional neurotransmission of dopamine, while
Parkinson's disease is associated with decreased dopamine levels. Dopamine concentrations in the
cerebral cortex decreased in response to intracrainal injection of stannous 2-ethylhexanoate, while the
concentration of dopamine metabolites DOPAC and HVA increased. This increased dopamine turnover is
consistent with the results of the open field test, and may account for the rats increasing (rather than
decreasing their locomotion distance with repeated testing). Norepinephrine and serotonin are two
neurotransmitters related to emotion, emotional behavior, stress, and hormone secretion. Serotonin levels
increased while norepinephrine levels decreased post intracranial injection with stannous 2-
ethylhexanoate; such disturbances in these neurotransmitters may cause dystrophy or depression.
Yamada et al, held that the neurodegenerative qualities of stannous 2-ethylhexanoate should
prevent its use as a catalyst in the synthesis of PLA and its copolymers intended for use in drug delivery.
Large manufacturers of PLA and its copolymers have used and continue to use stannous 2-ethylhexanoate
as a catalyst and it is unlikely they will remove stannous 2-ethylhexanoate from their process without
definitive proof of its toxicity.
IV What Environmental Legislation Exists that Might Apply to Med Dev?
A plethora of environmental legislation exists today, most of which describes hazardous chemical
reporting requirements. The legislation most pertinent in proving the utility of designing for the
environment impose reduction demands on the use of the most hazardous chemicals, two examples of this
type of legislation are the Massachusetts Toxics Use Reduction Act (TURA) and the European Union's
Registration Evaluation Authorization and Restriction of Chemicals (REACH).
IV.1 Massachusetts Toxics Use Reduction Act
The Massachusetts Toxics Use Reduction Act""' was enacted to promote pollution prevention in
businesses within the Commonwealth of Massachusetts. The Massachusetts Legislature first passed the
Massachusetts Toxics Use Reduction Act (TURA) in 1989, and most recently amended it in 2006
(Chapter 188 of the Acts of 2006). The Toxics Use Reduction Act requires large quantity toxics users
(those using 25,000 lbs/year or more of a toxic substance) to perform two tasks: 1.) to report the
manufacture, processing, or use of toxic chemicals and 2.) to prepare and follow a toxics use reduction
plan. Massachusetts businesses have reduced their toxics use by 41% and have curtailed their toxic by
product production by 65% through compliance with TURA.
The TURA covers the toxic chemicals detailed in the lists established through the following pieces
of federal legislation:
Section 313 of Emergency Planning and Community Right to Know Act (EPCRA) [42 U.S.C. S1101 et seq
Sections 101 (14) and 102 of Comprehensive Environmental Response, Compensation and Liability Act
(CERCLA) [42 U.S.C. S9601 et seq]
The administrative council on toxics use reduction may further classify the substances found in these lists
as higher or lower hazardous substances (with Persistant, Bioaccumulative, and Toxic Substances being
automatically classified as higher hazardous substances).
The first task required by the TURA in regards to the listed toxic or hazardous substances entails
reporting the manufacture, processing, and use of toxic chemicals. Large quantity toxics users (using
25,000 lbs/year or more of a toxic substance) with more than ten full time employees operating under SIC
codes 10-14, 20-39, 40, 44-51, 72, 73, 75, or 76 must file reports with the United States Environmental
Protection Agency (EPA) and the Massachusetts Department of Environmental Protection (DEP)
detailing each toxic or hazardous substance manufactured, processed, or used at a given facility. Even
when a facility is exempt from reporting, reports should be completed for each toxic substance used and
kept on record. A full toxics use report includes:
1
Reporting Requirements Xmd
These reports identify the large quantity toxics user, the facility, the production unit, and the toxic or
hazardous substance manufactured, processed, or used. The reports are maintained both by the
appropriate agencies (the US EPA and the MA DEP) and the facility filing them.
The Toxics Use Fee (MGL Chapter 21.1, Section 19) is based on the number of employees a facility
employs and is comprised of a base fee supplemented by a $300 fee per toxic or hazardous substance up
to a prescribed maximum fee level:
Number of Employees Base Fee Maximum Fee
10< employees <50 $500 $1,500
50< employees <100 $750 $2,000
100< employees <500 $1,250 $4,000
500< employees $2,500 $8,000
Table 2: Toxics Use Fee Schedule"v
These fees are not exorbitant, nor are they intended to be, they are meant to call attention to toxic
chemical use and not to penalize it, the proceeds from the fees are used to fund toxics use reduction
research and programs conducted by the Toxics Use Reduction Institute and the Office of Technical
Assistance.
The second task required by the TURA for listed toxic or hazardous substances is the preparation
and completion of a toxics use reduction plan. Toxics use reduction refers to the mitigation or elimination
of toxic or hazardous substances in a production process through the implementation of process or raw
materials changes. These changes should reduce risks for employees, citizens, and the environment in a
manner that does not redistribute those risks. A number of toxic use reduction techniques exist and
include:
Toxic Use Reduction Techniques
Raw material substitution
Product reformulation
Production unit redesign/modification
Production unit modernization
Improved operation and maintenance of production unit equipment and methods
Recycling, reuse, extended use of toxics
Table 3: Toxic Use Reduction Techniques
Each of the toxic use reduction techniques capitalize on substitution, process efficiency
improvements, or recycling to affect toxic use reduction. Raw material substitution implies replacement
of a toxic or hazardous substance with its non-toxic, non-hazardous counterpart, while product
reformulation implies replacement of a toxic or hazardous end product with an innocuous one, in order to
reduce toxics use. Production unit redesign/modification and production unit modernization both rely on
design improvements and the resultant efficiency benefits to curtail toxics use. Improved operation and
maintenance of production unit equipment and methods implies toxics use reduction through efficiency
improvements made using existing equipment (either by cleaning the equipment more frequently, better
or operating under more preferable conditions). Finally, recycling, reuse, and extended use of toxics
implies introduction of less naive toxic substances into the production process as the process
approximates a closed loop system.
The toxics use reduction plan required by TURA outlines measures a facility will take to lessen
their use of toxic substances and should include (according to Massachusetts General Laws, Chapter 21.I:
Section 11. Toxics Use Reduction Plan):
a.) An economic/technical assessment of each proposed technique for toxics use reduction,
including cost of implementation and any anticipated cost savings
b.) An analysis of current/projected toxics use, by products, and emissions
c.) An assessment of the types/amounts of toxic or hazardous substances in use
d.) A schedule for implementation
Each toxic use reduction plan must be certified by a toxics use reduction planner and the plan must be
updated and recertified after 2 years. Once a company has filed 1 toxic use reduction plan and 2 plan
updates, it may file: a.) another update, b.) an alternative resource conservation plan, or c.) implement an
Environmental Management System (EMS).
The DEP may further impose a performance standard on large quantity toxic users within a particular
user segment, under Massachusetts General Laws, Chapter 21.1: Section 15. Performance Standards,
which will require said users to achieve a prescribed level of by-products generated per unit of product
within a reasonable time (not to exceed 3 years).
The toxics use reduction plan is meant to facilitate compliance with various environmental legislation,
but as its implementation requires time, it can also delay compliance. A large quantity toxics user may,
under Massachusetts General Laws, Chapter 21.1: Section 16, petition the DEP for a temporary waiver of
laws/regulations administered by the DEP, if said user intends to achieve compliance with those
laws/regulations through the implementation of their toxics use reduction plan.
IV.1.1 Implications of Massachusetts Toxics Use Reduction Act on Med Dev
Presently, Med Dev has fewer than 10 employees and does not use 25,000 lbs of toxic or hazardous
substances, nor is it likely that Med Dev will use 25,000 lbs of these substances in the future. Med Dev
does however use two of the toxic or hazardous substances covered by this legislation, namely
dichloromethane and n-hexane. If the producers of dichloromethane and n-hexane were to discontinue
manufacturing these substances, it would disrupt Med Dev's supply chain of raw materials which would
in turn hinder Med Dev's ability to produce its hydrogel until such a time as it could find a suitable
alternative. The Massachusetts Toxics Use Reduction Act highlights the important role that Design for the
Environment has in ensuring Med Dev's supply chain is secure: by designing toxic substances out of the
process from the beginning Med Dev will not succumb to production stoppage when a toxic or hazardous
substance is pulled off the market.
Furthermore, while Med Dev may not produce a large enough quantity of material to be subject to
TURA today, complying with TURA is an intelligent strategy, as future legislation may extend TURA's
applicability to small quantity generators (SQG) or very small quantity generators (VSQG). Even without
TURA's applicability being extended to SQG, and VSQG, though, the type of environmental stewardship
highlighted in this legislation will aid Med Dev in conducting more cost effective operations, by reducing
the amount of hazardous waste generated.
IV.2 European Union's Registration Evaluation Authorization and Restriction of Chemicals
(REACH)
The European Union's Registration Evaluation Authorization and Restriction of Chemicals
(REACH)' legislation went into effect on June 1, 2007 and is currently being implemented in a phased
manner. This legislation serves to consolidate the fragmented laws and regulations concerning safe
chemical use within the European Union and places the onus on the chemical manufacture or user to
identify and assess risks, rather than on public authorities.
A company's first obligation under REACH is Registration, all substances manufactured or
imported in quantities of 1 ton or more must be registered with the European Chemicals Agency (ECHA).
Failure to register a substance will nullify a company's right to manufacture or import that substance.
Exemptions from this legislation include polymers and substances adequately regulated under
other legislation, such as medical products covered by the following two pieces of legislation":
Manufacturers and importers of substances which may be used in medicinal products, as active, inactive,
or excipient ingredients do not have to register under REACH. This exemption only applies to the
manufacturer or importer of a substance used in medicinal products, to the extent that that substance is
used for that particular use, quantities of the substance used for other uses must be registered under
REACH.
Registration is comprised of two documents which provide information on substances, risks arising
from their use, and measures used to ensure risks are managed: the technical dossier and the chemical
safety report (CSR). The technical dossier"' is filed for substances manufactured or imported in
quantities of 1 ton or more and identifies the manufacturer/importer, the substance, uses of the substance,
guidance on safe use, study summaries of Annexes VII to XI testing, indication that the dossier was
reviewed by an assessor, proposals for testing, and exposure information. The chemical safety report' i
(CSR) is filed for substances manufactured or imported in quantities of 10 tons or more and documents
hazards associated with the substance as well as exposure scenarios. The exposure scenarios included in
the CSR describe how the substances are manufactured or used during their life cycle, and how
environmental/human exposures are controlled.
Registration is a lengthy process and in order to prevent redundancy and redoubled efforts the
European Chemicals Agency (ECHA) allows joint submission of registrations for a particular substance.
When joint submission is used, a lead registrant compiles the majority of the information for the technical
dossier and CSR, while the others individually submit their company details and production volumes. The
ECHA has set up a forum, called the Substance Information Exchange Forum (SIEF) to help registrants
find one another. This is particularly important in light of the downstream user requirement of the
REACH legislation, as it requires coordination between the industrial user of a chemical and its
manufacturer. The downstream user (i.e. industrial user of a chemical) is required to consider their safe
use of the substance, ensuring their use is covered in the manufacturer's registration. Based on the
information downstream users obtain from their supplier, they must apply appropriate risk management
techniques.
Evaluation is the second piece of the REACH legislation and entails both dossier evaluation and
substance evaluation.
1.) Dossier evaluation
Compliance check: 5% of dossiers subject to check, ECHA checks compliance of registration
dossier against regulation requirements
Checking of testing proposals: all testing proposals subject to check, performed by ECHA to
prevent unnecessary animal testing
2.) Substance evaluation
Agency and competent member state Authorities request additional info on a substance to
clarify suspicions of risk
Evaluations performed by the ECHA may lead to the conclusion that further control of a substance is
necessary under the Authorization or Restriction provisions of REACH.
The authorization provision of the REACH legislation is provided as a central mechanism to
regulate substances of very high concern through a process where risks are vigorously assessed,
considered, and decided upon by the Community. Substances that constitute the very high concern
category warranting authorization include:
Carcinogenic, Mutagenic, Reproductive Hazards (CMR) category I or 2
Persistent Bioaccumulative and Toxic (PBT)
Very Persistent, very Bioaccmulative (vPvB)
Substances with similar effects as identified on a case by case basis
The use of authorized substances will not be banned by default. Authorization applications must include
an analysis of possible substitutes, measures being taken to research/develop possible substitutes, and if a
substitute exists, a substitution plan. An authorization will be granted if risk from the use of the substance
can be controlled, or that its socio economic benefits outweigh the risks and no suitable alternatives exist.
Authorizations are reviewed on a schedule and if suitable substitutes arise prior to a review, the
authorization may be amended or withdrawn. A downstream user may apply for their own authorization
for use of a substance of very high concern or may use the substance from an authorized manufacturer
provided their use is within the use scenarios covered in the manufacturer's application.
The restriction provision of the REACH legislation may prohibit the manufacture, marketing, and use
of substances that pose an unacceptable risk to human health and the environment. The member states in
conjunction with the ECHA on behalf of the European Commission prepare the proposals for restrictions
in the form of a structured dossier.
IV.2.1 Implications of REACH on Med Dev
REACH currently has an explicit exemption for medicinal products and therefore does not pose an
imminent concern for Med Dev. Furthermore the chemicals used in Med Dev's synthesis are not classified
as substances of very high concern (none are CMR category 1 or 2, PBT, or vPvB), only dichloromethane
(otherwise known as methylene chloride) is classified as a CMR category 3, where its carginogenic and
mutagenic behaviors are only probable not proven. However, the regulation is fairly new and may be
amended or otherwise subject to change, thus it should be monitored.
Furthermore, while the exemption dismisses manufacturers from reporting on substances used for
medicinal products, they are still obligated to report on the same substance used in different applications;
the exemption is only partial. The partial nature of the exemption may leave Med Dev vulnerable to
possible supply chain disruptions, where manufacturers finding it too expensive or difficult to comply
with legislation may discontinue producing a substance. A prime example of this is the impending
European Community ban on dichloromethane in paint strippers (this ban was prompted by carbon
monoxide poisoning deaths associated with using dichloromethane based paint strippers in improperly
ventilated areas, of which there had been 3 in the 5 years preceding 2007 according to the European
Chlorinated Solvents Association (ECSA)xXX). The graph in Table (X) demonstrates the breakdown of
sales of dichloromethane in the European Union's 25 member states plus Norway, Switzerland, and
Turkey by application for 2005. According to this graph, pharmaceuticals account for 51% of
dichloromethane sales, while paint stripping accounts for 13%, and solvents or auxiliary agents account
for 18%.
Breakdown of Sales of Dichloromethane in Europe
Figure 5: Breakdown of Sales of dichloromethane in the EU25 plus Norway, Switzerland, and Turkey;
the data was adapted from a report to the European Commission Directorate-General
Enterprise and Industry by Risk and Policy Analyst, Limited entitled: Impact Assessment of
Potential Restrictions on marketing and use ofDCM in paint strippers' to prepare this chart.
In dollar and cents terms (based on a dichloromethane price of $750/ton), an outright ban on
dichloromethane would account for a $9,750,000 loss in revenues to dichloromethane manufacturers
whose sales are approximately $82,500,000.
Application Category Tonnage Sold in Europe Revenue based on $750/ton of DCM
Pharmaceuticals 50,000 $37,500,000
Paint strippers 13,000 $9,750,000
Adhesives 5,000-10,000 $3,750,000-$7,500,000
Aerosols 1,000-5,000 $750,000-$3,750,000
Mechanical/Electrical 1,000-5,000 $750,000-$3,750,000
Degreasing Agents
Extraction in food industry 1,000-5,000 $750,000-$3,750,000
Coating 1,000 $750,000
Solvents or auxiliary agents in: 10,000-25,000 $7,500,000-$18,750,000
Foam blowing (polyurethane) 1,000-5,000 $750,000-$3,750,000
Polycarbonate production 1,000-5, 000 $750,000-$3, 750,000
Triacetate production 1,000 $750,000
Degreasing 1,000 $750,000
Other 5,000-10,000 $3,750,000-$7,500,000
Total 110,000 $82,500,000
Table 4: Breakdown of sales of dichloromethane in EU25 plus Norway, Switzerland, and Turkey as
well as estimation of revenues based on a price per ton of DCM of $750, this data is exactly
as it appears in the report to the European Comission Directorate-General Enterprise and
Industry by Risk and Policy Analyst, Limited entitled: Impact Assessment ofPotential
Restrictions on marketing and use ofDCM in paint strippers "".
* pharmaceuticals
* paint stripping
a adhesives
a aerosols
a mechanical degreasing agents
a extraction process in food industry
* coatings
a solvents or auxilary agent
Such a loss (13% or $9,750,000 out of $82,500,000) is probably insufficient to end dichloromethane
production altogether, especially where it is produced as a byproduct in chloroform manufacture, however
it may serve to drive prices of dichloromethane down due to oversupply.
Table 5 summarizes the scenarios that could arise from a ban on DCM use in paint strippers. The first
scenario assumes that the price of DCM would not change as a result of the ban and total revenues would
only fall by the amount of revenues accounted for by paint strippers. The second scenario assumes that
not only would total revenues reduce by paint strippers revenues, but that the ban would result in an over
capacity of dichloromethane forcing the price per ton down to $675 (10% less than $750). The third
scenario assumes that over capacity resulting from the ban would decrease the dichloromethane price by
50%, as in scenario two not only would the amount of dichloromethane sold be less, but the cost per ton
would also be less ($375/ton).
Scenarios if DCM were banned in paint strippers Total Revenue from sales of DCM
Total DCM revenue without paint strippers $72,750,000($750/ton)
Total DCM revenue without paint strippers with 10% price drop $65,475,000($675/ton)
Total DCM revenue without paint strippers with 50% price drop $36,375,000($375/ton)
Table 5: Summarizes the effects of banning paint strippers on overall sales of DCM, the first scenario
assumes that the price of DCM is unaffected by the DCM ban, the second scenario assumes
that due to over capacity (and therefore oversupply) of DCM its price will drop by 100/%, while
the third scenario assumes that DCM price will drop by 50% due to oversupply. The idea for
these scenarios was again adopted from the report to the European Committee Directorate-
General Enterprise and Industry by Risk and Policy Analyst, Limited, entitled: Impact
Assessment ofPotential Restrictions on Marketing and use ofDCM in paint strippers"'.
Considering that dichloromethane accounts for 13% of the European market share, it is unlikely its
ban would drive prices down 50% due to overcapacity, it is more likely that prices would not be driven
down at all or by 10%. With prices driven down 10% (to $675/ton) by overcapacity, the total revenue
from DCM sales would be $65,475,000, which represents a fall of -21% from the total sales of DCM
without a paint stripper ban ($82,500,000). Even a 21% drop in revenues is probably not enough to
destroy the DCM industry, however this analysis shows the detrimental affects restrictions and bans can
have on revenue streams. Even if a restriction or ban is imposed on a chemical for use outside the
pharmaceutical industry, that same ban can have repercussions within the pharmaceutical industry. If stiff
enough or far reaching enough, a ban may cause a manufacture to discontinue manufacturing a product
that is critical to a pharmaceutical company's supply chain, forcing the pharmaceutical company to
scramble to find alternatives, undergoing costly recertification with the FDA and production stoppages in
the process.
The graph in Figure 6 demonstrates the breakdown of sales of dichloromethane in the United States
by application in 2006 " . According to this graph, pharmaceuticals account for 12% of dichloromethane
I I
sales, while paint stripping accounts for 40%, chemical processing accounts for 10%,
products account for 20%.
and formulated
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Figure 6: Breakdown of US dichloromethane demand for various application categories in 2006 data
was adapted from a Halogenated Solvents Industry Alliance, Inc, White Paper on Methylene
Chloride".
Paint strippers represent a much larger percentage of dichloromethane sales in the United States as
compared to in the EU (40% vs 12%). The US pharmaceutical industry and the EU paint stripper industry
account for an identical percentage of dichloromethane demand (12%) in their respective markets. While
the US paint stripper industry and the EU pharmaceutical industry account for similarly higher
percentages of dichloromethane demand (40% and 51% respectively) in their respective markets. The fact
that the percentage of dichloromethane demand is higher for paint strippers as compared to
pharmaceuticals, whereas in the EU the opposite is true, indicates that the effect of a paint stripper ban in
the US would be much more pronounced on the overall dichloromethane market.
Paint Stripping Pharmaceuticals
Sof US DCMdemand 40% 12%
% ofEU DCM demand 12% 51%
US industry demand 33,560 10,068
EU industry related demand 13,000 50,000
US industry related revenues $25,170,000 $7,551,000
EU industry related revenues $9,750,000 $37,500,000
Table 6: Comparison of % of total DCM demand, industry (i.e. paint stripping, pharmaceutical) related
demand, and industry (i.e. paint stripping, pharmaceutical) related revenues for the US and EU.
All data were compiled from ECSA and HSIA sources, previously identified.
In dollar and cents terms (based on a dichloromethane price of $750/ton), an outright ban on
dichloromethane would account for a $25,170,000 loss in revenues to dichloromethane manufacturers
whose sales are approximately $62,925,000.
Application Category Tonnage Sold in US Revenue based on $750/ton of DCM
Pharmaceuticals 10,068 $7,3551,000
Paint strippers 33,560 $25,170,000
Chemical processing 8,390 $6,292,500
Formulated products 16,780 $12,585,000
Metal cleaning 6,712 $5,034,000
Foam manufacture 4,195 $3,146,250
Other 4,195 $3,146,250
Total 83,900 $62,925,000
Table 7: Breakdown of sales of dichloromethane in the US as well as estimation of revenues based on a
price per ton of DCM of $750 (adopting the ECSA's price for DCM) adapted from a
Halogenated Solvents Industry Alliance, Inc, White Paper on Methylene Chloride".
Such a loss (40% or $25,170,000 out of $62,925,000) is probably insufficient to end dichloromethane
production altogether, especially where it is produced as a byproduct in chloroform manufacture, however
it may serve to drive prices of dichloromethane down dramatically due to oversupply.
Table 8 summarizes the scenarios that could arise from a ban on DCM use in paint strippers. As in the
European Union analysis, the first scenario assumes that the price of DCM would not change as a result
of the ban and total revenues would only fall by the amount of revenues accounted for by paint strippers.
The second scenario assumes that not only would total revenues reduce by paint strippers revenues, but
that the ban would result in an over capacity of dichloromethane forcing the price per ton down to $675
(10% less than $750). The third scenario assumes that over capacity resulting from the ban would
decrease the dichloromethane price by 50%, as in scenario two not only would the amount of
dichloromethane sold be less, but the cost per ton would also be less ($375/ton).
Scenarios if DCM were banned in paint strippers Total Revenue from sales of DCM
Total DCM revenue without paint strippers $25,170,000($750/ton)
Total DCM revenue without paint strippers with 10% price drop $33,979,500
($675/ton)
Total DCM revenue without paint strippers with 50% price drop $18,877,500(1375/ton)
Table 8: Summarizes the effects of banning paint strippers on overall sales of DCM, the first scenario
assumes that the price of DCM is unaffected by the DCM ban, the second scenario assumes
that due to over capacity (and therefore oversupply) of DCM its price will drop by 10%, while
the third scenario assumes that DCM price will drop by 50% due to oversupply. The idea for
these scenarios was again adopted from the report to the European Committee Directorate-
General Enterprise and Industry by Risk and Policy Analyst, Limited, entitled: Impact
Assessment ofPotential Restrictions on Marketing and use ofDCM in paint strippers" and
information from the HSIA White Paper on Methylene Chloride was used"
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Considering that dichloromethane accounts for 40% of the US market, its ban may drive prices
down 50% due to overcapacity, though it is almost certain that prices would be driven down by 10%.
With prices driven down 10% (to $675/ton) by overcapacity, the total revenue from DCM sales would be
$33,979,500, which represents a fall of -46% from the total sales of DCM without a paint stripper ban
($62,925,000). A 46% drop in revenues may be enough to destroy the DCM industry, if it foresees
continued bans and restrictions on DCM use. Even if a restriction or ban is imposed on a chemical for
use outside the pharmaceutical industry, that same ban can have repercussions within the pharmaceutical
industry. Again, if stiff enough or far reaching enough, a ban may cause a manufacture to discontinue
manufacturing a product that is critical to a pharmaceutical company's supply chain, forcing the
pharmaceutical company to scramble to find alternatives, undergoing costly recertification with the FDA
and production stoppages in the process. If a ban on dichloromethane based paint strippers were to be
invoked in the United States as opposed to Europe, it could have a more crippling effect on the overall
dichloromethane market (since paint strippers account for 40% of the overall demand in the US as
compared to 12% in the EU) and might force pharmaceutical companies to scramble to find suitable
substitutes against a backdrop of costly FDA re-validation and production stoppages.
IV.3 An Act for a Competitive Economy through Safer Alternatives to Toxic Chemicals
The Massachusetts state legislature is currently working on an Act for a Competitive Economy
through Safer Alternatives to Toxic Chemicals". This legislation seeks to augment the environmental
gains made through compliance with the Toxics Use Reduction Act, by encouraging companies to
explore safer alternatives in addition to reducing their toxics use. Furthermore, this legislation echoes the
provisions calling for solvent substitution under the Authorization portion of REACH, in an attempt to
ensure that the 37% of Massachusetts business which export to the EU remain competitive under
REACH. The legislators and stakeholders in favor of this legislation hope chemical substitution will
result in a cleaner environment and a safer work place with reduced health care costs, worker illnesses,
and turnover.
Under the safer alternatives legislation, the administrative council will identify 2 to 5 priority toxic
substances from a list of chemicals of high concern and the Toxics Use Reduction Institute will prepare
safer alternative assessment reports analyzing whether safer alternatives exist for those substances " . The
list of chemicals of high concem is comprised of CMR category 1 and 2, PBT, and vPvB substances and
relies on government lists of chemical categorization for its composition. The safer alternatives
assessment report prepared by the TURI will:
Safer Alternatives Assessment Report
1.) Iden the use and fnction of a priority toxic substance, select a subset of uses for further
2.) Identify whether alternatives exist for these uses and functions
3.) Identify whether any existing use is unnecessary
4.) Research relevant factors to characterize feasible alternatives
5.) Provide a qualitative assessment of economic viability, opportunity, and cost associated with
adopting or implementing safer alternatives
6.) Identify the uses of the priority toxic substance which do not have suitable safer alternatives, and
recommend possible R&D initiatives
7.) Use chemical categorization lists to identify potential safer alternatives
~ _~
*This information is provided in An Act for a Competitive Economy through Safer Alternatives to Toxic
Chemicals, redraft in progress to Senate no. 2481 (January 12, 2009), MGL Chapter 21I.Section 5, 24(b)
A company manufacturing a priority toxic substance in MA must file a notice with the DEP within
120 days of learning of its designation. This notice will identify the substance, its distribution within MA
(amount and concentration), the uses of the substance, the name and address of the manufacturer.
In addition to the safer alternatives assessment report, the TURI will work in conjunction with the MA
DEP and OTA to complete a chemical action plan which shall set out specific actions a company must
take in regards to their priority toxic substance and the schedule for actions. The actions covered by the
action plan include implementing safer alternatives when feasible or when infeasible ensuring tight
control over human and environmental exposure. In addition, where substitution is costly this legislation
has created an "Assist Businesses to Compete" Fund (ABC Fund) overseen by the OTA to facilitate the
transition"". Each chemical action plan will be presented to the administrative council on toxics use
reduction by the DEP and shall then be reviewed by the public, prior to adoption. The DEP may compile
regulations to restrict the use of a priority toxic substance covered by the chemical action plan subject to a
substitution deadline and the specification of a suitable alternative by the DEP.
Massachusetts General Law Chapter 21.1 Section 26 (3) of an Act for a Competitive Economy
through Safer Alternatives to Toxic Chemicals indicates that a priority toxic substance user may apply to
the DEP for a waiver from a substitution deadline if no economically or technically feasible safer
alternative exists. The waiver application will include:
Waiver Application for Safer Alternatives to Toxic Chemicals substitution deadline
1.) Identify the specific use of the priority toxic substance for which the waiver is sought
2.) Identify all the alternatives considered and their costs
3.) Identify the basis for finding no suitable alternatives
4.) Provide documentation of minimization efforts to be made in regards to the use/exposure of the
priority toxic substance until a suitable alternative is found
5.) Comment on steps the applicant will make to determine a safer alternative in 3 years
*This information is provided in An Act for a Competitive Economy through Safer Alternatives to Toxic
Chemicals, redraft in progress to Senate no. 2481 (January 12, 2009), MGL Chapter 21I.Section 26(3)
Violation of this legislation shall result in punishment by fines of up to $25,000/day for each day a
company is out of compliance. In addition a Safer Alternatives in Products Fee is under consideration,
this fee shall apply to Massachusetts wholesalers and distributors of products containing priority toxic
substances exceeding a de minimis threshold. These fines should not be very large as the legislation in its
draft form describes raising $2 million from all manufacturers/users in the first year escalating up to $6
million plus in years after year 3 (each year new priority toxic substances will be introduced, thus the
burden will be shared).
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IV.3.1 Implications of an Act for a Competitive Economy through Safer Alternatives to Toxic
Chemicals on Med Dev
Massachusett's Act for a Competitive Economy through Safer Alternatives to Toxic Chemicals is
much more restrictive and more comprehensive than the European Union's REACH regulations. Where
REACH has provisions for the exemption of materials used in medicinal products, the Massachusetts
legislation only provides for de minimis thresholds and waivers to substitution deadlines. The
Authorization provision under the REACH legislation, which calls for phased in substitution, probably
has broader applicability as it encompasses all manufacturers/importers/users of substances of very high
concern (CMR category 1 and 2, PBT, and vPvB substances) whereas the Massachusetts legislation only
applies to 2-5 priority toxic substances (i.e. a subset of the substances of very high concern) per year. The
risk associated with the Massachusetts legislation is significantly reduced thanks to the limited number of
substances it covers, however a vast amount of uncertainty exists over which priority toxic substances
will be identified for substitution next. Due to the severity of the restrictions (essentially substitute or
bust) and the few provisions the legislation provides for avoiding substitution and substitution deadlines,
especially the fact that there is no provision for medicinal products, this legislation is very worrisome.
Med Dev would probably not have to make safer alternative substitutions under this legislation in the
sense that the amount raw materials they use would probably not exceed the de minimis threshold.
Furthermore the hazardous raw materials that Med Dev does use: n-hexane, diethyl ether, and
dichloromethane, would not be considered substances of very high concern (and therefore probably would
not be designated as priority toxic substances). Dichloromethane is the closest to a substance of very high
concern that Med Dev uses in its manufacturing facility and it is only a CMR category 3. If the DEP,
TURA, and the OTA were to force substitution of dichloromethane through this legislation (without the
provision for its use in medicinal products), it is probable that dichloromethane manufacturers would
cease to provide dichloromethane to Massachusetts. Though Massachusetts is small and would not
effectively put a dichloromethane manufacturer out of business altogether, the cost of doing business in
Massachusetts would become prohibitive and distributors would discontinue supplying DCM to
Massachusetts. Without a supplier of dichloromethane in the state, Med Dev would be forced to make the
costly post market substitution of DCM incurring costs of FDA re-registration/re-testing and production
stoppage along the way, not to mention an inability to provide their product to patients who desperately
need it. In light of such legislation it is wise to design for the environment and avoid having to make
costly substitutions in the future.
IV.4 Legislation Overview
Although none of the legislation discussed (TURA, REACH, or the Safer Alternatives Legislation)
pose a direct and imminent threat to Med Dev's ability to pursue its manufacturing plan in its current
form, it should raise awareness of potential future supply chain disruptions. Solvent. substitution and
designing for the environment could aid Med Dev in avoiding potentially costly re-validation and
production stoppages due to supply chain disruptions, by eliminating toxic or hazardous substances from
the outset. Foresight and environmental action will not only lead to a better, more robust process, but will
also result in a reputation of environmental stewardship.
V. What are other Pharmaceutical Companies Doing?
Med Dev is a medical device manufacturer, however where their medical device is a polymeric
material many parallels may be drawn between Med Dev's process and those of more traditional
pharmaceutical companies producing complex organic molecules. The vast scale differences between
Med Dev and large pharmaceutical companies, pharmaceutical companies being substantially larger than
Med Dev, may drive pharmaceutical company's decisions to pursue green manufacturing, as the
regulations described above have a more direct effect and significant cost savings (on permitting as well
as raw materials) may result. Pfizer, Merck, and many other large pharmaceutical companies have
realized significant waste reduction and therefore cost savings through implementing green chemistry
initiatives; these initiatives have also been recognized with awards as shown in table 9.
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Table 9: Description of green chemistry improvements and awards received by Pfizer and Merck."Af
The synthetic organic chemistry methods used by Med Dev and other pharmaceutical companies
generate emissions, effluents, and waste that are potentially adverse to human health and the environment,
this piece of analysis describes the steps pharmaceutical companies have taken to minimize their
environmental impact. Below is a plot of hazardous waste generated by the major pharmaceutical
companies over a six year period (normalized by millions of $ of sales in order to facilitate comparison),
from this plot it is evident that pharmaceutical companies are beginning to decrease their hazardous waste
generation through green chemistry initiatives.
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Figure 7: Normalized (by $m sales) Hazardous Waste generated by each of the major pharmaceutical
companies over a 6 year period. The information for this plot was obtained from each
company's corporate responsibility report and their annual financial reports. X
In addition to achieving overall reductions in the amount of hazardous waste generated, the
pharmaceutical industry is directing special attention toward reducing their dichloromethane consumption
in view of intensifying regulation concerning its use. Glaxo Smith Kline has decreased its
dichloromethane use by 50% while Merck plans to begin a campaign to eliminate the use of the solvent,
and Pfizer has reduced its dichloromethane use by more than 50% (as shown in the figure below).
Figure 8: Pfizer's Dichloromethane use from 2004 to 2007 for their Groton, Sandwich,
facilities has decreased by more than 50%.'
and La Jolla
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While the cost savings and regulatory avoidance issues may not be as compelling for Med Dev, Med Dev
can use this analysis to benchmark which steps it can take to operate in an environmentally more
favorable way. Also, since Med Dev may aspire toward acquisition, building green chemistry into their
manufacturing processes early may make them a more appealing acquisition target.
V.1 Merck
Merck and Co. published its first environmental report and announced its first set of environmental
improvement goals in 1990 and have been committed to assessing their environmental footprint ever
since. Merck evaluates its environmental footprint on the basis of the following dimensions: energy and
water use, greenhouse gas and pollutant emissions to air and water, and waste generation and recycling
rates. This discussion will focus on emissions, effluents, and waste as green house gas generation and
energy and water use are outside the scope of this analysis.
Pharmaceuticals are comprised of complex organic molecules and the processes used to synthesize
these molecules are often multi-step batch operations that require numerous solvent changes and
extensive solvent based cleaning between batches. Merck had revenues of $24 billion in 2007 and
purchases approximately 30 million kg of solvent/year. Solvents are an integral part of pharmaceutical
synthesis and formulation and constitute a majority of Merck's effluents, emissions, and wastes.
Through a program to track their effluents, emissions, and waste, Merck is able: to identify areas
where their environmental footprint can improve, to evaluate the impact of new projects, and to
understand their progress against environmental goals. Beginning with the original design of their
manufacturing processes, Merck tries to incorporate green chemistry techniques that will prevent
pollution. The green chemistry techniques applied to new product development include using alternate,
less toxic synthesis routes, designing efficient processes that significantly reduce the amount of raw
materials used, substituting toxic solvents with their innocuous counterparts, replacing solvent based
cleaning methods with water based ones, reusing and/or recycling spent solvents, and employing in-
process as well as end of pipe treatment technologies and controls for solvent emissions. Each of these
methodologies reduce or prevent emissions, effluents, and wastes, resulting in decreased costs associated
with new solvent purchase and waste treatment. In 2007, Merck generated 54,000 metric tons of
hazardous waste, 56% of which was reused in the manufacturing process. Of the solvent streams Merck is
incapable of reusing 23% are reused by industries with less strict purity standards, 32% are burned for
energy generations, 44% are treated and disposed of (of which less than 4% are landfilled)". Merck also
reports their emissions of volatile organic compounds (VOCs) and toxics reduction inventory (TRI)
substances, this number has remained relatively flat (around 400 metric tons of VOC/yr, and
approximately 120 metric tons of TRI substances/yr) over the five years, 2003 to 2007, reported in their
Corporate Social Responsibility Reporti".
Merck also participates in promoting green chemistry initiatives in the broader pharmaceutical
industry by belonging to the American Chemical Society's (ACS) Green Chemistry Institute (GCI)
Pharmaceutical Roundtable and Pharmaceutical Industry Principles for Responsible Supply Chain
Management (PhRMA) which aims to ensure suppliers practice environmental responsibility. Merck also
takes additional measures to understand the effects of the final products on the environment
(Pharmaceuticals in the Environment (PIE) testing).
A few case studies on Merck's environmental performance serve to demonstrate Merck's
commitment to green chemistry. Interestingly, both the EMEND and Januvia processes were changed
post clinical trials. Large pharmaceutical companies may be able to afford post approval changes,
especially in light of the long term return on environmental process improvements (both from a legislative
and efficiency perspective), however the best strategy for green chemistry implementation remains:
design for the environment.
Merck Case Studies
Dr. Viviane Massonneau, Merck's director of Global Science, Technology, and Commercialization
leading Chemical Small Scale Synthesis Pilot Plants discussed her impression of Merck's green chemistry
initiatives in a phone interviewiv. Merck is making strides to improve their environmental track record,
however their progress is slow and they lag behind other pharmaceutical companies like Pfizer and GSK.
Presently, the Environmental and Process Safety Engineering group (which Dr. Massonneau formerly led)
assesses a process for viability and safety when it is transitioning from Process Research to Scale Up, an
assessment which typically is characterized by a significant amount of paperwork. A reagent assessment,
that would use a color coded system to signify the environmental implications of reagents used in a
particular synthesis (red would indicate a reagent is bad for the environment, yellow a reagent is tolerable,
and green a reagent is not a concern) is slowly being added to the overall safety assessment, however it
lacks coordinated alternative suggestions. The reagent assessment system Merck is implementing will
allow them to identify environmental hazards in their process, but it will not help them to replace those
hazards with more benign alternatives.
In addition, Merck has yet to create many of the web based green chemistry tools that could help
facilitate their employees use of green chemistry principles, for instance Pfizer has electronic laboratory
notebooks that suggest alternative chemicals when a protocol contains a hazardous one. Merck also has
not performed many of the lifecycle analysis on nor has it taken a holistic approach to its operations,
thereby leaving many of the opportunities for environmental improvement undiscovered. Merck is slowly
beginning to track the atom efficiency ((molecular weight of desired products/molecular weight of all
products) x 100%) and the process mass intensity (quantity of raw materials input (kg)/quantity of bulk
active pharmaceutical ingredient (API) output (kg)) of its reactions in an effort to identify their
inefficiencies. Their major focus is on promoting efficiency, which can lead to reductions in solvent
consumption resulting in cost savings both from the purchasing and disposal perspectives.
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A number of the decisions Merck makes regarding purchasing, outsourcing, and even acquisition
hinge on environmental performance. If a start-up would like to be acquired by a large pharmaceutical
company, Dr. Massonneau argues, their environmental track record will be one of the factors integrated
into the decision making process. Furthermore, Dr. Massoneau stressed there are chemicals Merck
already avoids using today due to their toxicity, including: ethylene oxide, chloroform, and benzene.
Merck is presently evaluating the potential of eliminating the use of dichloromethane in their operations
as well.
Dr Massonneau felt green chemistry's greatest impact on Merck as an organization would result
from instituting green thinking from the beginning; if the scientists in Medicinal Chemistry were well
versed in green chemistry, they could help make syntheses green by design. While processes can be
changed further along in development cycle, often times later stage changes are associated with costly
process benchmarking or re-validations, even when repeat clinical trials are unnecessary there is a
considerable expense involved in changing the process.
Merck believes that implementing green chemistry is not only a mechanism for improving their
environmental footprint, but also for ensuring they remain competitive in the future. And while being
competitive is paramount, a positive public perception is also important, Dr. Massonneau quoted one
source as saying that the allied chemical industry had an approval rating of 26%, placing them just ahead
of the nuclear and tobacco industries in the public's perception, surely something has to be done.
V.2 Astra Zeneca
Astra Zeneca is trying to integrate health, safety, and environmental concerns across its
organization and throughout the life cycle of its products. Their goals for promoting environmental
sustainability include: considering environmental implications through the process, product, and
packaging development processes, reducing waste and emissions generation, and avoiding the use of
hazardous substances wherever relevant. To achieve these goals, Astra Zeneca has employed a number of
strategies to promote green chemistry.
One strategy, called the "SHE Triggers" model is used in the early stages of manufacturing
process development for new active pharmaceutical ingredients (API) and aids in the identification and
elimination of potential safety, health, and environmental issues. The "SHE Triggers" model has been
incorporated into secondary manufacturing process development as well as pharmaceutical products
development (including packaging and devices).
Another strategy employed by Astra Zeneca is a Green Chemistry Network linking chemists and
engineers within process development with environmental specialists, who aid them in integrating
principles of green chemistry. The Green Chemistry Network's environmental specialist use a tool kit that
incorporates: a solvent selection guide, acid/base, alkylating agent, and amide formation reagent selection
guides, a substance avoidance database, and an active pharmaceuticals ingredient removal technology
selection tool, to aid them in teaching green chemistry to process development. The solvent selection
guide gives the process development scientist/engineer assistance in selecting the most environmentally
friendly solvents. The acid/base, alkylating agent, and amide formation reagent selection it enables
intelligent selection of reagents based on their environmental considerations. The substance avoidance
database chronicles substances on all the relevant environmental regulation lists (UK, Europe, Sweden,
US), highlighting substances to be avoided and offering alternatives in their stead. The API removal
technology selection tool provides assistance in identifying the most appropriate effluent treatment
technology.
In 2007, a training session was held to educate Astra Zeneca's Global Process Research and
Development employees about their role in minimizing the environmental impact of the manufacturing
processes they were responsible for designing. Astra Zeneca is also working with more than 30 of their
outsourcing partners to ensure the environmental impacts of their manufacturing processes are tracked
and understood, through measuring waste production for instance. On a broader scale, Astra Zeneca
works to promote the implementation of green chemistry principles through its membership in the
American Chemistry Society Green Chemistry Institute's Pharmaceutical Roundtable. Astra Zeneca also
promotes green chemistry education through its Green Chemistry Summer School and its AZ Green
Chemistry and Engineering Grant.
Astra Zeneca's stance on waste minimization is one of prevention through continual improvement
of existing processes, improved design of new processes, improved purchasing processes, and internal
waste awareness programs. Whenever possible solvents are recycled and reused to minimize fresh solvent
requirements and emissions abatement equipment is installed to prevent release of hazardous chemicals
(i.e. volatile organic chemicals) to the environment.
V.3 Schering Plough
Schering Plough has a Sustainable Chemistry Initiative that aims to promote the use of renewable
reagents and the consideration of safety and the environment in the design of manufacturing processes. A
Green Chemistry Kick-off meeting was held in their Werthenstein Operations in Switzerland to initiate
their green chemistry commitment. Presently, Schering Plough hosts bimonthly Green Chemistry Forums
in their Chemical and Physical Sciences unit, in addition to giving external presentations to educate a
broader audience about Green Chemistry.
Schering Plough has developed and updated (as of 2007) a Chemical Selection Guide which uses a
color coded system to indicate the environmental impact of the chemicals listed: green (environmentally
acceptable), yellow (conditionally acceptable), and red (use caution, consider alternatives), so that those
with the least environmental impact may be chosen. In addition, a "Pathways to Greener Solvents" poster
was distributed within the Chemical Development and Discovery division. Schering Plough also launched
a web-based Process Sustainability Index (PSI) database that captures the sustainability of new products
in development. In 2007 Schering Plough used the following green chemistry principles in its operations:
solvent substitution and recycling, atom efficiency, in situ elimination of cyanide waste, continuous
distillation, use of supercritical fluid chromatography, and enzymatic approaches.
V.4 Novartis
Novartis was named a super sector leader in healthcare for the Dow Jones Sustainability Index
which tracks the economic, environmental, and social performance of sustainable companies worldwide.
Novartis waste management strategy like that of most pharmaceutical companies emphasizes waste
prevention followed by reduction, recycling, and reuse.
V.5 Eli Lilly
Eli Lilly is diligently pursuing green chemistry in its new production processes to ensure safer,
environmentally more sound operations. Lilly has used a number of innovations to integrate green
chemistry into the thought processes of their scientists and engineers.
Chemists at Lilly use electronic lab notebooks equipped with green chemistry tools that indicate
when less hazardous alternatives exist and that give feedback on the efficiency of the process. Process
development scientists and engineers use a system of check points to ensure efficiency and hazardous
material use are within set boundaries. At each of the check points the efficiency factor (raw material
input/unit of active pharmaceutical ingredient produced) is calculated, where it does not meet the
efficiency factor standard a management review is triggered. The use of these new technologies (for
instance replacing conventional batch reactors with coiled tube reactors) has enable Lilly to realize a 100
fold reduction in raw materials use.
In addition to monitoring and improving their own processes, Lilly assesses their third party
suppliers during the selection and implementation processes to ensure they have sufficient health, safety,
and environmental standards. Lilly uses a 5 step process to conduct an assessment on a 3 rd party supplier,
the first step is to build an understanding of the 3rd party's EHS program, then to perform a material risk
review, followed by an on-site assessment, and finally to provide Lilly EHS materials to the company and
assist them in meeting the necessary EHS standards.
V.6 Bayer
Bayer has made a number of operational improvements in their pursuit of green chemistry, most
notably BaySIS which is an internet based tool for capturing health, safety, and environmental data
(HSE). When on-site reporting mangers enter their data into BaySIS, the system cross and plausibility
checks it and then incorporates it into a five year trend map. Another operational improvement Bayer has
made is the integration of health, safety, environment, and quality (HSEQ) into a single high quality
management system.
V.7 Bristol Meyers Squibb
Bristol Meyers Squibb intends to manufacture sustainable products that have as little effect on the
environment as possible through initiatives that promote green chemistry, packaging reductions, and
process safety. To meet these goals, Bristol Meyers Squibb has established specific programs to improve
the EHS profiles of its key suppliers, sustainability awards to acknowledge their employees' sustainable
behaviors, and leadership development programs to help integrate EHS throughout the company. Bristol
Meyers Squibb has been aggressively targeting packaging use reduction through innovative packaging
design, increased recycled content, and the use of environmentally sound materials. Within their
pharmaceuticals processes, Bristol Meyers Squibb aims to use renewable materials whenever possible.
A specific example of Bristol Meyers Squibb's efforts to use renewable materials is in the
manufacture of Taxol. The active ingredient in Taxol, paclitaxel, is derived from the bark of yew trees
found in the the Pacific Northwest. The yew trees were being killed when their bark was harvested,
endangering the habitat of the spotted owl and threatening the sustainability of paclitaxel production, thus
scientists investigated alternatives and found that twigs and needles from yew shrubs would also yield
paclitaxel.
Bristol Meyers Squibb has set a goal of reducing their off-site emissions of chemicals it lists as
priority reduction chemicals by 50% (from 2002 levels) by 2010. In classifying chemicals as priority
reduction chemicals, Bristol Meyers Squibb considers the level of regulation applicable to the chemical
and whether the chemical contributes to process hazards/health hazards. Presently their priority reduction
chemicals include: acetonitrile, benzene, alkyl acetate, methyl isobutyl ketone, methanol, methyl-t-butyl
ether, n-butyl acetate, tetrahydrofuran, toluene, and most notably methylene chloride (i.e.
dichloromethane).
V.8 Pfizer
As the first pharmaceutical company to hire a full time green chemistry lead responsible cross
functional teams spanning the globe, Pfizer has a strong commitment to green chemistry. Pfizer
incorporates environmental, health, and safety (EHS) considerations throughout the lifecycle of its
products, from raw material sourcing, to research and development, to manufacturing, and through to end
use and recycling/disposal. A quote from Kuzemko et al in their article in Organic Process Research and
Development summarizes Pfizer's role in promoting green chemistry best:
"The industry gold standard for a pharmaceutical process in which solvent usage and recycling
scenarios are considered would be the Viagra (sildenafil) process... The details of this manufacturing
process were disclosed, and more importantly, significant development efforts were undertaken to set this
benchmark for the pharmaceutical industry. "'v
Pfizer's green chemistry initiatives revolve around discovering innovative ways to enhance process
robustness, reduce emissions and hazardous materials use, and increase recycling. Thus far Pfizer has
worked to identify and replace hazardous solvents, to reduce its overall solvent usage, to perform reagent
change out, and to minimize waste. Such green initiatives have helped Pfizer conserve energy, realize cost
savings on new and established products, and gain public recognition for their green efforts.
In order to facilitate Pfizer's green chemistry initiatives multi-disciplinary teams composed of
chemists, engineers, and EHS professionals work collaboratively to first identify opportunities for EHS
process improvements and then implement those improvements. These chemists, engineers, and EHS
professionals use internally developed guides to aid them in the selection of environmentally responsible
solvents and reagents. In addition, Pfizer participates in a number of community outreach programs to
educate the populous about green chemistry. Pfizer sponsors on-site workshops and site visits for
undergraduate and graduate students highlighting their use of green chemistry in achieving sustainable
product development. Pfizer is also developing green chemistry curriculum for middle and high school
students and actively participates in national and international conferences, seminars, and workshops
focused on green chemistry.
A number of specific examples of the inroads Pfizer has made in implementing green chemistry in its
campaigns exist. Pfizer was able to achieve a 65% reduction in the total organic waste (3.5 million L/year
of methanol and tetrahydrofuran) and eliminate liquid nitrogen use in one step of the synthesis of Lipitor,
their blockbuster high cholesterol drug. Process improvements in the third generation synthesis of Lyrica
(a drug used for neuropathic pain associated with diabetes or shingles) resulted in the elimination of 5
million gallons of solvent per year and more than 150 tons of nickel catalyst. Pfizer won the top European
Green Chemistry award, the Excellence in Green Chemistry and Engineering Award for their
accomplishments in Lyrica process improvement. Pfizer utilized novel process innovations including a
highly selective coupling reaction and a ultra efficient intermediate synthesis to design away 25,000
metric tons of waste per year in its Vfend (an antifungal medication) campaign. In 2003, Pfizer won the
UK's IChemE award (the Crystal Faraday Award for Green Chemical Technology) by significantly
reducing the annual organic process waste burden (from 4,300 to 300 tons/yr) associated with the
production of Viagra. Pfizer won the US EPA's 2002 Presidential Green Chemistry Award for green
chemistry improvements in the synthesis of Zoloft that doubled process yield and significantly reduced
the process's environmental burden.
Pfizer's commitments to green chemistry extend beyond their processes to those of their suppliers and
contract manufacturers, in 2007, Pfizer conducted 140 EHS audits of its suppliers, 27 follow up reviews,
and provided coaching on EHS standards to 19 of its suppliers. In addition Pfizer helped develop the
Pharmaceutical Supply Chain Initiative which attempts to standardize EHS competencies across suppliers
to the pharmaceutical industry.
V.9 Glaxo Smith Kline (GSK)
Glaxo Smith Kline (GSK) has identified five priority areas of focus to ensure the environmental,
health, and safety profiles of the chemicals it uses and produces are as innocuous as possible: 1.) hazard
assessment and communication, 2.) substitution of hazardous chemicals, 3.) transparency, 4.) supply
chain management, and 5.) sustainable chemistry.
Hazard assessment and communication requires that GSK identify the hazards intrinsic in its process
through an EHS assessment. Where information regarding a hazard is unavailable within GSK methods to
obtain information from suppliers and the literature should exist. Once adequate information is gathered
about process hazards it should be shared with relevant stakeholders including employees, contract
manufacturers, and suppliers to enable them to manage the hazards properly.
Substitution of hazardous chemicals involves categorizing certain chemicals as having priority for
substitution, then assessing whether feasible, less hazardous alternatives for those chemicals exist. When
developing new products emphasis should be placed on identifying instances where a less hazardous
alternative exists and making the appropriate substitution. In existing manufacturing processes, "priority
chemicals" replacement should be pursued if it is technically and economically feasible, otherwise
appropriate risk management measures should be employed to ensure adverse effects are minimized. GSK
realizes that implementing substitution in an existing process requires considerable effort to ensure that
the substitute does not affect the overall chemistry of the process and that the efficacy and/or patient
safety profile has not been altered, therefore substitution is primarily pursued in new process
development.
Transparency, whenever competitive advantage is not lost in the process is pursued by GSK to ensure
that their stakeholders understand what constitutes a "priority chemical" and what progress is being made
in terms of eliminating or otherwise substituting "priority chemicals". Furthermore, GSK shares their risk
management practices for the continued use of "priority chemicals" and the EHS data on its products, to
ensure adverse environmental impacts are minimized.
Supply chain management helps GSK ensure that its internal EHS standards are met throughout its
supply chain from contract manufacturers to suppliers. GSK conducts pre-contract EHS evaluations and
periodic EHS audits of their suppliers and contract manufacturer to ensure that consistent EHS standards
are maintained. GSK selection criteria for suppliers or contract manufacturers, requires that robust EHS
management systems and responsible care programs are maintained.
Sustainable chemistry initiatives at GSK aim to minimize chemical use (and therefore waste) through
implementation of process design and process efficiency innovations. Wherever possible GSK strives to
use safer alternatives to hazardous chemicals, where that is impossible GSK seeks to manage their EHS
risks effectively. Furthermore, GSK explores opportunities to use renewables, biotransformations, and
inherently safer chemistry; while optimizing recycling and reuse.
GSK has designed an Eco Design tool kit to aid their employees in addressing the 5 priority areas
outlined above. This tool kit includes a Green Chemistry and Technology guide, Materials guide, Green
Packaging Guide, a Fast Lifecycle Assessment for Synthetic Chemistry (FLASC) tool, and Chemicals
Legislation Guide. The Green Chemistry and Technology guide provides information on how to improve
efficiency, reduce environmental impacts, and minimize costs through green chemistry. The Materials
guide summarizes the environmental impacts of solvents and reagents. The Green Packaging guide aids in
the selection of environmentally sound packaging materials. The Fast Lifecycle Assessment for Synthetic
Chemistry (FLASC) is a web-based tool to help identify the environmental impacts of a synthesis and
offer greener alternatives, it is used to compile a environmental scorecard for each campaign. The
Chemicals Legislation Guide (CLG) provides a quick reference on hazardous substance legislation. Green
chemistry metrics are collected for each potential new drug in development to determine whether raw
materials are being used efficiently, what hazardous chemicals are being employed and their possible
environmental impacts, this information is then used to determine whether a new drug should be
promoted or not.
In light of the fact that pharmaceutical companies typically use approximately 100 tons of raw
material for every ton of active pharmaceutical ingredient produced, GSK has committed to a goal of
doubling the material efficiency of its manufacturing processes for new products from 2006 by 2010.
One relatively simple example of where GSK has made strides in improving its environmental
footprint can be found in their replacement of batch manufacturing with continuous manufacturing in
their production of toothpaste. In switching from batch to continuous manufacturing GSK was able to
reduce their annual costs by forty five thousand pounds, reduce raw material consumption by 24.5
tons/year, and reduce water consumption by 20 million L/year.
V.10 Big Pharma considerations weigh on Med Dev
All of the major pharmaceutical companies are actively investigating ways to make their processes,
and those of their suppliers, more environmentally friendly on the grounds of reputational as well as
economic gains. These companies are placing increasing environmental scrutiny on not only their
suppliers, but also their acquisitions, thus if Med Dev wishes to pursue acquisition as a growth strategy,
the environment should be factored into their process design.
VI. Hurdles to Green Chemistry? How do they affect Med Dev?
Product designers face constant pressure to devise new products in a faster, cheaper manner and it
is against this backdrop that green chemistry must attempt to vie for their time and attention. Time to
market considerations are particularly crucial in a start-up environment, like Med Dev's, where the
company's operations are essentially cash flow negative until its first product successfully enters the
market. A staged approach to implementing green chemistry practices in manufacturing may be
appropriate for companies where time is of the essence, where the changes which are quickest/involve the
least amount of change or are projected to be costly to change in the future (i.e. requiring FDA re-
validation) could be implemented first, with other incremental improvements being made according to a
schedule.
Another method of facilitating design for the environment is through the creation of a green
chemistry team which identifies areas in the design which could be improved with green chemistry
techniques. Admittedly a green chemistry task force would be difficult to establish within a start-up
employing 7 people, however a start-up may look toward external sources, such as the Massachusetts
Office of Technology Assistance (OTA), to assist them in identifying green opportunities.
Yet another method of ensuring green principles are designed into a process is the use of a design
checklist/framework, which would direct a designer to consider the environment at various stages in the
design process. Comprehensive checklists are not generally part of a start-up, like Med Dev's modus
operandi, however implementing such a systemic approach to designing for the environment may ensure
that considerations that would otherwise be ignored would be included in the design.
Certainly green chemistry initiatives aid in cutting costs, but those cost cutting provisions are not
always inherently obvious up front, such savings are often long term rather than near term. Start-ups with
funding limitations often do not have the luxury of expending in the short term to see long term benefits;
their focus is the present. In fact, a start-up may argue against incurring the expense of designing for the
environment upfront while funds are tight, when deferring such decisions until a larger company acquires
them or they became a publicly traded entity would be less financially cumbersome. The large company
acquisition scenario, would transfer the responsibility for environmentally responsible operations to the
acquirer. With environmental standards becoming more and more stringent today and companies focusing
on their environmental performance from cradle to grave, there is a strong possibility that a company's
environmental report card may become a determining factor in its ability to be acquired. In the publicly
traded scenario, the company maintains responsibility over its early environmental choices, which may
have legacy implications on process efficiency and waste generation. Furthermore, with indexes like the
Dow Jones Sustainability Index and the FTSE4 Good Index gaining ground, it is likely that investors of
the future may invest contingent upon a company's environmental performance. In the end, designing for
the environment may be more costly (though it might also cost the same or less) in the short term, the
only true way to identify its impact on a company's bottom line is through a holistic view of the process
using Life Cycle Assessment techniques.
One of the greatest concerns medical device companies have in regards to making environmentally
driven post-approval process changes is whether they'll have to conduct a revalidation for the FDA. Such
a concern is valid, since the FDA rigorously regulates process changes and since revalidation would
undoubtedly involve additional, costly clinical trials. Designing a robust quality management systems
(QMS) when filing with the FDA may ensure that post approval changes may be made without the
necessity of a FDA review and validation. According to "An Environmental Guide for the Medical
Device Industry in Massachusetts"' vi many medical device companies make environmentally driven
process changes without seeking revalidation from the FDA.
VII. What possible avenues can Med Dev pursue to Green their manufacturing process?
Med Dev has limited influence over the environmental performance of its first generation product as
they rely on a supplier (Boehringer Ingelheim) to provide them a synthesized polymer (PLGA). The
PLGA synthesis represents the least environmentally favorable portion of Med Dev's first generation
production process. Although Boehringer Ingelheim largely dictates how PLGA is produced, Med Dev
could attempt to educate them about possible greener alternatives, like solvent substitution. Boehringer
Ingelheim's production method was discussed in the section detailing Med Dev's first generation
production process and is considered the industry standard, however another greener methodology is
emerging and Med Dev may attempt to source their materials from this alternate source.
A limited liability corporation between Cargill and Teijin Limited of Japan called NatureWorks,
LLCvii has devised a method to ferment lactic acid from corn, using an estimated 65% less fossil fuel and
reducing their green house gas emissions by 80-90% compared to producing traditional petroleum based
polymersviii. Deriving polymers from natural annually renewable materials, represents a huge
environmental gain as compared to their synthetic derivation. Their process consists of the following
steps":
1.) Farmers harvest corn and it is sent to a milling plant
2.) The corn is cooked for 30-40 hrs at 122 0 F at the milling plant causing it to swell and soften,
the resultant water is used later in the process and in the production of animal feed
3.) The corn mixture is machine ground and screened to isolate starch, which is then converted
into sugar
4.) The sugar is converted into lactic acid by microorganisms in the fermentation process
5.) The lactic acid molecules combine to form oligomeric lactide rings
6.) The oligomeric lactide rings are opened through a condensation reaction to form a long chain
polylactic acid polymer
The final polymerization step described above (ring opening polymerization through condensation)
typically results in low molecular weight polylactic acid polymers, thus for NatureWork's polymer to be
used for Med Dev's purposes, in medical devices, the polymerization methodology would have to change.
Unfortunately, even a polymerization method change would not suffice to make sourcing NatureWork's
polylactic acid a possibility, as they do not allow the use of their polymer for medical purposes. An
inquirylix to NatureWorks, LLC to determine whether they were currently partnering with any
pharmaceutical/medical device companies to supply PLA as a feedstock for polymer synthesis garnered
the following response:
"NatureWorks LLC customer agrees that, unless permitted by NatureWorks LLC in writing, customer will not use
or allow others, including their customers, to use IngeoM biopolymer or products made from NatureWorks'
biopolymer, in the following:
(i) Components of or packaging for tobacco products.
(ii) Components of products intended for human or animal consumption.
(iii) In any application that is intended for any internal contact with human body fluids or body tissues.
(iv) As a critical component in any medical device that supports or sustains human life.
(v) In any product that is designed specifically for ingestion or internal use by pregnant women.
(vi) In any application designed specifically to promote or interfere with human reproduction."'
While NatureWorks' nature based plastic is not presently available for Med Dev's use, more
naturally synthesized polymers may be available in the future and could become an important part of Med
Dev's green manufacturing strategy for its first generation product.
Med Dev is more directly responsible for the environmental performance of its second generation
product, as it performs the polymer hydrogel synthesis itself. In the second generation polymer synthesis,
the substances of greatest environmental concern include: dichloromethane, diethyl ether, hexane, and
stannous 2-ethyl hexanoate. Environmentally benign alternatives to each of these toxic or hazardous
substances have been identified and the discussion that follows is a proposal for designing for the
environment. In this proposal, dichloromethane will be substituted by a less toxic solvent, while diethyl
ether, hexane extraction will be replaced with supercritical carbon dioxide extraction.
Solvent substitution requires the least modification to an existent synthetic process of any approach
to green manufacturing, however easy substitutes do not always exists and care must be taken not to
replace a highly toxic substance with a marginally less toxic substance. When evaluating possible
solvents for substitution three things must be considered: 1.) the physical and chemical properties of the
original solvent, 2.) the EHS profile desired, and 3.) the reagent (i.e. solute) solvent interactions.
Dichloromethane is capable of dissolving many organic molecules, has favorable physical properties (it
is a weak Lewis Base), is inert toward reagents and reaction conditions, and can be used in oxidations,
organometallic reactions, Lewis Acid reactions, and functional group interconversions" . The major
impediments to continued use of dichloromethane include its toxicity and its low boiling point (390 C).
Water or phosphate buffered saline (PBS) should be not be considered when choosing possible substitutes
for dichloromethane in the synthesis of PEG-co-poly(lactic acid) diacrylate, as the reagent acryoyl
chloride is hydrolysable.
Ogawa et al"' identified benzotrifluoride (C6H5CF3) as an attractive alternative for dichloromethane,
as it has a relatively low toxicity and price, is slightly less polar than dichloromethane, but more polar
than ethyl acetate. Benzotrifluoride has not been used extensively as an organic solvent, however it is
capable of dissolving a number of organic solutes. Ogawa et al conducted head to head (dichloromethane
to benzotrifluoride) reactions to determine the suitability of benzotrifluoride as a substitute for
dichloromethane. The reactions demonstrated included: derivatization of alcohols, oxidation of alcohols,
and carbon-carbon bond formation. Through these reactions Ogawa et al showed that benzotrifluoride
was a appropriate substitute for dichloromethane, though its freezing point may be too high for certain
applications, it is susceptible to reduction, and it may be hydrolyzed by aqueous acids a high
temperatures.
Gani et al" devised a 4 step solvent selection process for solvent substitution using a computer aided
molecular design (CAMD) technique. In step 1 the functions of the solvent to be substituted are
identified from the process description, functions include: the ability maintain inertness while dissolving a
reactant, the ability to isolate the product, or the ability to serve as a intermediate wash. In the second
step, search criteria are devised, these search criteria are called R-indices and indicate the physical and
chemical properties, EHS characteristics, and operational properties of a solvent. Target alternatives may
be identified by setting upper and lower bounds on the values of the search criteria, where all solvents
falling within the bounds are considered. In the third step, the search is performed, where a list of solvent
candidates that fall within the R index bounds outlined in the search criteria step is generated and then
assigned RS indices according to the rules laid out in table 10. In step 4, those solvent candidates with RS
indices are assigned scores (S) according to the following scale:
RS Index Correspond"ng S score
1 10
2 8
3 6
4 4
5 1
Table 10: Definition of S scores. Given the RS index, the corresponding S score is shown.
Any solvent receiving an S score of 1 will be eliminated from contention. Once the list of solvent
alternatives has been generated, then each solvent on the list must be investigated for substitution through
laboratory experiments. Head to head comparisons between the solvent to be substituted and the
substitute are conducted, and successful candidates will demonstrate behavior identical to that of the
original solvent.
Gani et al applied this search methodology to identify substitutes for dichloromethane. The
dichloromethane being substituted was used to inertly dissolve reactants in a reaction (the exact purpose
Med Dev uses dichloromethane for). The R indices formulated during the search criteria identification
included:
R index Value Meaning
RO Solvent addition required to improve reactants
R1 1 Reaction occurs in liquid phase
R2 278 K Reaction temperature is278K
R3 1 Solvent must dissolve reactants
R4 0 Solvent does not need to dissolve products
R5 1 Solvent must have phase split with water
R6 1 Solubility parameters for DCM are known
Solvent must be inert toward
reactants/products
RS 1 Solvent should not associate/dissociate
R9 1 Solvent should have desirable EHS properties
Table 11: R-indices identified for dichloromethane in Gani et al's study' m
Once the R-indices were identified, they were used as criteria to perform a search of a solvent database
for possible candidates. Ethyl acetate, isopropyl acetate, ethyl propionate, toluene, and
methylcyclopentane were identified as possible candidates and assigned the following RS indices
according to the rules laid out in table 12:
Solvent RS2 RS3 RS5 RS6 RS7 RS8 RS91 RS92
Ethyl acetae 1 1 1 2 N/A 1 3 2
Isopropyl acetate 1 1 1 3 N/A 1 2 3
Ethylpropionate 1 1 1 2 N/A 1 2 3
Toluene 1 1 1 3 N/A 1 2 2
Methyleyclopentane 1 1 1 3 N/A 1 2 2
Table 12: RS indice for possible dichloromethane substitutes, generated by Gani et al'
The RS values were then assigned their corresponding S scores, and any solvent receiving
was eliminated from consideration.
an S score of 1
Solvent S2 S3 S5 S6 S7 S8 $91 592 Score
Ethyl adetate 10 10 10 8 N/A 10 6 8 62
Isopropyl acetate 10 10 10 6 N/A 10 8 6 60
Ethylpropionate 10 10 10 8 N/A 10 8 6 62
Toluene 10 10 10 6 N/A 10 8 8 62
Methylcyclopentane 10 10 10 6 N/A 10 8 8 62
Table 13: S scores corresponding to the RS indices for possible dichloromethane substitutes, generated
by Gani et aly
Ethyl acetate, isopropyl acetate, ethyl propionate, toluene, and methylcyclopentane were all identified as
suitable substitutes for dichloromethane using Gani et al's 4 step computer aided molecular design
methodology. The true test for whether these proposed substitutes will be truly suitable is a head to head
laboratory comparison between a process performed using dichloromethane and the same process being
performed with the proposed substitute. A successful substitute will demonstrate identical behavior to
dichloromethane and will not affect the resultant products characteristics in any way.
Rule
RUle A: Establish need for
solvents
Rle B: Liquid-phase reactions
Rul C: The solvent must he
liquid at the reaction
temperature
Rule D: Need the solvent as a
arrier
Rult E:Need solvent to remove
products
RIe F: Need for phase split
Rure G: Matching of solubility
pjrameters of solute and
solvent
Rile H: Neutrality of the solvent
Rule 1: Associationidissociation
properties of the solvent
RIe J: EHS property constraints
Reaction index calculation (R,) Reaction-solvent indices calculation (RS,)
Ro= I N/A
If R= I. and if the reaction nust bhe occurring in the
iquid phase. set R: = 1. Otherwise, set R7 =0
Ri = scified reaction temperature
If one or more reactants are solids (or large
molecules) set R3= 1. Otherwise. set R3 = 0
If one or more of the products are solid (or large
mnolecules), set R M I. Otherwise. set R4 = 0
If phase split is necessary, set Rs= I. Oth w ise, set
R4 = 0
f RJ 1 Ior R4 = 1. then Re = 1. Otherwise. Re =0
If R= I orR4 .= I.setR = 1 if the solvent must be
neutal to all the compounds present in the reacting
system Otherwise, set R =0
If the solvent must not associate or dissociate, set
R,= 1. Otherwise. set R6a= 0
If EHS properties are to be used as constraints. set
Ra 1. Otherwise, set R a 0. Since there are a
number of EHS properties. each A and its
corresponding RSo index has a second subscript to
identify the specific EHS property. RS3, correspond
to LC_~ and RSEl corresponds to log Ko.
N/A
Remove the solvents from the candidates list that are not
likely to he liquid at R: = 20 K. where R2 is the specified
reaction temperature. That is to say, the melting point of
the solvent must bhe lower, and the boiling point must be
higher. than the reaction temperature. Note that values for
RS- are needed only if R i
If R3  l. solvent s needed as a carrier for the reactant in
the liquid phase. Assign RS values according to the
following rules: RS = I. if reactants are totally miscible:
RS = 2, if reactarats are highly soluble: RSI = 3, if
ractants are soluble: R5 =4. if reactants are slightly
soluble: R.S =5. if reactants are not soluble
If t = I. solvent is needed to remove the product from the
reacting phase. Assign RS values for solvents according
to the following rules: RS4 = 1. if products are totally
miscible: RSIi 2 if products are highly soluble: RS4 3.
if products are soluble: R Ss = 4. if products are slightly
soluble: R54 = 5. if products are not soluble
Ceate a LLE or a SLE diagram where the phase split can
be seen and according to this assign the RS indices
Create a graph with Harsen hydrogen solubility parameter
values aon X-axis and Hansen polar solubility parameter
values on Y-axis. In this way this index has been assigned
If R- a I. check for the solvent pK, slue for the feasible
solvents and assign RS wslues based on the following
rules: RS, = 1. if pK, >3; RS, a 2, if 2<pK, .>3 RS, = 3.
If I c <pKa2 RSr =4. if0<pK> I: RS,5, if pK <0
If R, 1. check for the solve molecule type data for the
feasible solvents and assign RS& alues based on the
following rules: RS = I. if solvent is non-polar; RS& 2
or 3. if solvent is polar non-associating: RS = 4. if solvent
i& associating: RS = 5, if solvent is ionic
If R9 = 1. then set the goal values for LC and logK 0.
and retriesve the solvent values for the corresponding
properties and assign the RS veltues according to the
following rules: RS a 1. if G, = G = 9: RS = 2. if
G, G= 10%: RS = 3. if G , =Gt 15%: RS =4. if
G = G 20%: RS, = 5. if Gs > G 20%. where G is the
goal value ofa specific EHS property G, is the
corresponding solvent property
Table 14: Appendix A Rules for calculating the Reaction Index (Ri) and the Reaction-Solvent (RSi),
copied verbatim from Rafiqul Gani, Paola Arenas Gomez, Milica Folic Concepcion Jimenez-
Gonzalez, David J C Constable, Solvents in Organic Synthesis: Replacement and Multi-Step
Reaction Systems, " Computers and Chemical Engineering, 32, 2008, pg 2420-2444.
While simply replacing a toxic solvent with another, less noxious solvent seems like a logical and
easy approach toward producing environmental benefit, the resultant outcome may not be the best.
MP
According to Fages et alL two thirds of pharmaceutical products are particulates, the majority of which
are generated via crystallization or precipitation. Supercritical processes serve as an environmentally
friendly alternative to precipitation for compounds which are susceptible to thermal stress, producing
highly pure micro/nano particles with narrow size distributions in a single step. A supercritical fluid is
any substance whose temperature and pressure are both higher than their corresponding critical point
values (Tc and Pc). The supercritical phase replaces distinct liquid and gas phase and the thermophysical
properties of supercritical fluids are unique from those of the liquids and gases.
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Figure 9: Phase diagram demonstrating critical temperature and pressure, as well as supercritical
fluid (adapted from http://en.wikipedia.org/wiki/Critical point (thermodynamics)) i
Supercritical fluids have liquid like densitities, high compressibilities, intermediate viscosities, and
substantially higher binary solute diffusion coefficients compared to liquidsii. Supercritical fluids are
capable of dissolving many nonvolatile, thermally labile substances; manipulation of this solvency over a
range of temperatures and pressures allows these fluids to be used as effective extraction agents.
Supercritical carbon dioxide, in particular, has been used extensively as an extraction agent in the
pharmaceutical, food processing, and other allied chemicals industries due to its innocuous nature: it has a
relatively low supercritical temperature (Tc= 31.04) and pressure (Pc= 72.8 atm), it is non-toxic and
nonflammable, and it will not leave a toxic residue. Three families of supercritical fluid processes exists:
Rapid Expansion of Supercritical Solutions (RESS), Supercritical Antisolvent (SAS), and Particles from
Gas Saturated Solutions (PGSS).
The RESS process is comprised of two steps, in the first the substance of interest is dissolved in a
supercritical fluid, while in the second the supercritical fluid/substance mixture is rapidly depressurized
through a nozzle. The rapid depressurization results in particle nucleation and generation. Figure 10
shows the process, liquid C02 is pumped through a pressure regulating pump to a heat exchanger where it
is superheated, then it is fed into the extraction autoclave where it mixes with the solute prior to being
expanded through a nozzle at the top of the expansion chamber.
Uquid C02I
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Figure 10: Schematic of the RESS Process, adapted from Fages et al"i
Expansion is an isenthalpic process in the single (vapor) phase zone of a pressure-enthalpy phase
diagram and occurs with a simultaneous drop in temperature.
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Figure 11: Pressure-Enthalpy and Pressure-Temperature phase diagram, showing isenthalpic expansion.
Notice that as the pressure decreases, the temperature also decreases. Adapted from Fages et
alL'
The starting temperature must be sufficiently high (360 K = 870 C) to avoid condensation/freezing of
the supercritical fluid post expansion, however thermo-labile solutes may be adversely affected. To
counteract the temperature drop upon expansion and avoid clogging of the nozzle, a heated nozzle or a
heating device upstream of the nozzle may be used. Solute nucleation is initiated by mechanical
perturbation upon sudden expansion and is predicated by operating conditions, the nature of the fluid, and
the length of the nozzle. During solute nucleation solute solubility falls several orders of magnitude on a
time scale of 10-4 to 10-6 s, leading to high super saturation ratios.
The super saturation ratio (S) is defined as the concentration of the solute divided by its solubility
(i.e. its concentration at saturation). Supercritical fluids are often capable of dissolving a particular solute
much more effectively than their ideal gas counterparts, as much as 105 or 106 times as effectively, this
phenomenon is captured in a parameter called the enhancement factor. The enhancement factor is the
ratio of the solute solubility in a supercritical fluid divided by the theoretical solute solubility in the
corresponding ideal gas. The enhancement factor phenomenon, implies that large supersaturation ratios
- - --
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can be obtained, when the supercritical fluid is expanded to an ideal gas. Large supersaturation ratios will
result in the formation of a large number of small particles, in fact particle size is dictated by
manipulating the pressure drop at the nozzle and/or the solute concentration (i.e. the supersaturation
ratio). A balance must be struck between generating very small particles with a high supersaturation ratio
and maintaining some pressure in the expansion vessel to facilitate recycling. The less a supercritical fluid
is perturbed from its initial pressure, the easier it will be to recycle.
The RESS process is not universally applicable, as some solutes are insoluble in supercritical carbon
dioxide. The solubility issue may be solved by using a different supercritical fluid, though other
supercritical fluids may be more hazardous than supercritical CO 2 and may require harsher supercritical
conditions. Entraining a co-solvent, such as ethanol or acetone, in supercritical CO2 may also facilitate
better solute solubility, but at the cost of employing a less environmentally friendly solvent. RESS has
been used encapsulate naproxen in poly(lactic acid)"6, where poly(lactic acid) is soluble in CO2; PEG on
the other hand is insoluble in CO2 and a co-solvent must be used in the RESS process to affect PEG
encapsulation of proteins like lysozyme and lipase" . The RESS process has been used in the
pharmaceutical industry for production of single constituent particles (aspirin and ibuprofen),
encapsulation, and coating of pre-existing particles. In addition, RESS has replaced traditional organic
solvent precipitation as the extraction method for decaffeination of coffee. Jung et all"' have performed
an extensive literature review on the use of RESS across various industries and their findings can be
found in appendix X.
The supercritical antisolvent (SAS) process overcomes the solute solubility limitations associated
with the RESS process, by using the supercritical fluid as an antisolvent. The solute is dissolved in a
solvent (ethanol, acetone, ethyl acetate, dichloromethane) and co-injected with a supercritical fluid
through a nozzle into an extraction vessel pre-charged with antisolvent (to achieve a specific pressure), as
shown in Figure 12. When a solute is added to a solvent/antisolvent system, there is less miscibility
between the solvent and antisolvent (i.e. a smaller antisolvent effect) as the solute competes with the
antisolvent for interaction with the solvent. Particle formation is facilitated by the collision of drops of
solute solution with the supercritical fluid phase, the supercritical fluid dissolves and then evaporates the
solvent lowering its solvent power forcing the solute to precipitate. Once particles are formed it is often
necessary to strip any entrained solvent by flowing fresh antisolvent (i.e. supercritical fluid) over them.
Nozzle SoluteSolution
HIlection
Heat Exchanger Device
LiquidCO2
cylinder
The SAS Process
Figure 12: Schematic of the SAS process. Adapted from Fages et al" 6v
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The solvent should be chosen based on its miscibility with the antisolvent, ability to dissolve the
solute, and its non-toxic nature. The optimal solvent-antisolvent miscibility can be determined by looking
at the phase behavior of the mixture, as postulated by Scott and Van Konynenburg and discussed in Lora
et all ', solvent-antisolvent systems with type I phase behavior (a single liquid-gas critical point, and no
liquid-liquid immiscibility) should be selected. Selection between type I solvent-antisolvent systems
should be dictated by the volatility of the solvent, as a more volatile solvent will be easier to remove from
the final particles.
The nozzle plays an important role in solute solution-antisolvent mixing and particle formation, as it
serves to increase the interfacial area and mass transfer rate of the solvent with the antisolvent by
uniformly injecting small liquid droplets into the continous supercritical fluid. Once the solute solution-
antisolvent droplets leave the nozzle, they are subjected to three forces: cohesive forces (i.e. surface
tension) that resist break up, velocity dependent friction between the droplets and the continuous
supercritical fluid in the extraction vessel, and turbulence within the droplets whose radial components
are no longer constricted once through the nozzle. Atomization, or immediate generation of very fine
particles upon nozzle clearance, is achieved when friction and turbulence forces are very large and can be
manipulated through choosing a low nozzle length to diameter ratio, pressurizing the extraction vessel,
and choosing a solvent with a low viscosity and surface tension.
Operating temperature and pressure are rather important, while a higher temperature might be
desired to promote solvent evaporation, it requires a simultaneous increase in pressure to ensure the anti-
solvent effect is still strong enough to affect precipitation. The pressure may be increased to the critical
point of the solvent/anti-solvent mixture, thereby creating two fully miscible components, enabling faster
mass transfer. The presence of the solute, however, raises the critical point and the associated critical
pressure may be too high for operation.
In the RESS process particulates are formed in the gas phase, while in the SAS process particulate
formation occurs in the supercritical C0 2-solvent mixture. A solute's residence time in the supercritical
mixture should be minimized in order to avoid such phenomenon as dissolution-recrystalization and
solid-solid transition which may cause polymorphs (different morphological forms of the particle to
form). Polymorphs are a particular issue in the pharmaceutical industry because of their potential to
perturb compound activity and shelf life. Kordikowski et al""' have demonstrated, through the choice of
the appropriate flowrate and operating temperature that polymorphs may be avoided. SAS has been used
with a wide variety of molecules such as antibiotics, proteins, and biopolymers owing to the fact that it
does not require solubility in supercritical CO2. Furthermore SAS allows for the co-precipitation of two
different compounds simultaneously resulting improved dissolution rates or drug release systems. Jung et
al"xxvii have also performed an extensive literature review on the use of SAS across various industries and
their findings can be found in appendix X.
The Particles from Gas Saturated Solutions (PGSS) process utilizes the fact that dense gases can be
dissolved in large quantities of liquids. Typically gaseous CO2 is dissolved to the point of saturation in a
solution-suspension of solute or a melted solid, then expanded through a nozzle into an expansion
chamber where particles are formed. The PGSS is widely used in polymer process where it has been
shown to modify glass transition and melting temperatures, as well as densitites.
VI. Economics of supercritical C02 for Med Dev
The laboratory process for generation of PEG-co-poly(lactic acid) diacrylate macromer requires three
diethyl ether precipitations and a hexane precipitation. The precipitations use large amounts of costly,
toxic solvents and result in the generation of polydisperse particles which lack reproduciblitity, so not
only are they terrible for the environment but they are also not very defensible against FDA regulations,
which require reproducibility. Approximately 9 L (6 L of diethyl ether and 3 L of hexaneb") of solvent
are used to generate 30 g of PEG-co-poly(lactic acid) diacrylate macromer in the second synthesis step, in
mass terms:
Solvent Volume (mL) Density (g/mL) Mass (g) Cost (based on
$64.50/L diethyl ether,
and $67.40/L
hexane)b
Hexane 3000 0.6548 1964.4 $202
Diethyl Ether 6000 0.7134 4280.4 $387
Total Solvent 9000 6244.8 $589
( Mass Macromer )100% 0.48%
Total Mass Solvent
Table 15: Summary of hexane and diethyl ether use in the second synthesis step for production of 30 g of
PEG-co-poly(lactic acid) diacrylate macromer. Densities obtained from Wikipedia"
Table 15 summarizes the amount of hexane and diethyl ether used in production of 30 g of PEG-co-
poly(lactic acid) diacrylate macromer, put in another way 200 times the mass of solvent is required to
make the final mass of macromer (6244.8 g solvent divided by 30 g of macromer), pointing to the
excesses inherent in precipitation processes.
Thar SFC, a division of Waters Corporation, manufactures supercritical CO 2 systems for particle
extraction, including supercritical antisolvent (SAS) and rapid expansion of supercrical solutions (RESS)
systems. Since PEG-co-poly(lactic acid) diacrylate macromer is polar and likely insoluble in carbon
dioxide, thus a SAS system is appropriate for Med Dev's needs. Thar SFC's SAS system is fully
integrated and is delivered ready to operate; the system includes a chilled pump head (to ensure liquid
CO2 is delivered to the preheater), a preheater, a back pressure regulator to ensure critical pressure is
maintained within the particle formation vessel, a particle formation vessel, and a collection basket and
two 0.5 pm stainless steel filters to ensure capture of particulates. The system is completely computer
automated and can be operated and monitored through a software interface. Thar SFC's SAS50 system is
capable of operating at CO 2 flowrates of 5-50 g/min and solution flowrates of 1-20 mL/min and its
particle formation vessel has a capacity of 500 mL, according to its product spec sheet"b .
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Number of
Solute solution Time required Total process Carbon Dioxide Amount of C2 bottles of CO 2  Cost of COz2flowrate for 3000 mL time (with Carbonrequired (based on
(mL/min) solute solution additional 120 flowrate (g/min) required (g) (based on 20000 $20/bottlek~(min) min wash) (min) g/bottle)
1 3000 3120 50 156000 7.8 $ 187.2
5 600 720 50 36000 1.8 $ 43.2
10 300 420 50 21000 1.05 $ 25.2
15 200 320 50 16000 0.8 $ 19.2
20 150 270 50 13500 0.675 $ 16.2
Table 16: Tabulation of the amount of carbon dioxide required for SAS extraction of PEG-co-poly(lactic
acid) diacrylate for various solute solution flowrates, based on the second synthesis step in the
30 g synthesis.
The table above summarizes the amount of carbon dioxide required for the SAS extraction of PEG-co-
poly(lactic acid) diacrylate for various solute solution flowrates for the second synthesis step for a 30 g
synthesis. Antisolvent use is much higher than diethyl ether and hexane (for instance for a solute flowrate
of 20 mL/min 13500 g of CO2 are required to affect the precipitation of the product, whereas only 6244.8
g of diethyl ether and hexane would be required to affect the same precipitation (nearly 2.2 times more
solvent is needed for the SAS process over the diethyl ether and hexane process). Assuming a solute
flowrate of 20 mL/min, approximately 450 times the mass of solvent is required to make the final mass of
macromer using supercritical CO2,(mass of CO2 required (assuming 20 mL/min solute flowrate) divided
by mass of macromer produced (13500 g/30 g)). The cost of materials is significantly less for carbon
dioxide (ranging from $43.20 to $16.20 for a 30 g synthesis depending on SAS solute flowrates between
5 and 20 mL/min respectively versus $589). The whole economic story however is only evident when the
cost of the Thar SFC SAS 50 system is taken into account, the system was quoted to Med Dev for
$68,115.00 xxxii. A breakeven analysis shows that an investment in the SAS50 system will pay off in 2.3
years for a solute flowrate of 20 mL/min and 2.4 years for a solute flowrate of 5 mL/min. These
calculations were based on 40,000 patients a year, with a market penetration of 40% (16,000 patients a
year), 0.3 mL hydrogel/patient, where the hydrogel is 30% (wt/vol) PEG-co-poly(lactic acid) diacrylate in
PBS. To meet this forecasted demand 1460 g of PEG-co-poly(lactic acid) diacrylate would have to be
produced each year.
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Figure 13: Break Even plot for supercritical CO2, showing that approximately 2.35 years are required to
achieve return on the SAS50 investment.
The calculations for this analysis can be found in the appendix and the results are illustrated in Figure 13,
above.
The catalyst stannous 2-ethyl hexanoate was found to be a neurodegenerative agent and although used
in very small quantities, its replacement might be beneficial. Stannous 2-ethyl hexanoate utilizes a
coordination-insertion mechanism to catalyze reactions and other possible catalysts employing this
mechanism included: aluminum alkoxides, and zinc derivatives. Aluminum alkoxides are not suitable
alternatives to stannous 2-ethyl hexanoate as aluminum has been found to promote Alzhiemer's disease.
Zinc derivatives, like zinc (II) lactate are nontoxic and commercially available, however laboratory scale
tests have demonstrated that zinc (II) lactate is less efficient than stannous 2-ethyl hexanoate. Another
class of catalysts that could work as possible substitutes for stannous 2-ethyl hexanoate include metal free
catalysts, which are both economical and environmentally friendly. The enzyme lipase is an excellent
example of such a metal free catalyst, it benefits from easy removal post processing, however it promotes
very low yields, making it less desirable as a substitute for stannous 2-ethyl hexanoate. Since stannous 2-
ethyl hexanoate is used in such minor quantities and a suitable efficient substitute does not exist for it, it
may be best to continue its use and carefully monitor so that excessive residues of the catalyst do not go
undetected.
VII.2 Cost Analysis of proposed solutions
A cost sensitivity analysis on the replacement of dichloromethane with ethyl acetate, isopropyl
acetate, ethyl propionate, toluene, methyl cyclopentane, or benzotrifluoride shows that the % change in
cost resulting from substitution ranges from -42% to 12%. The cost per liter of each of the substitutes and
dichloromethane are given in table 17 below as well as the cost of manufacturing 30 g of PEG-co-
poly(lactic acid) diacrylate (using 600 mL of dichloromethane (or substitute)).
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Possible substitutes Cost/L Cost of 600 mL % change
Ethyl acetate $55.70/L $33.42 -24.6%
Isopropyl acetate $63.50/L $38.10 -42.0%
Ethyl propionate $39.40/L $23.64 11.9%
Toluene $40.90/L $24.54 8.5%
Methyl cyclopentane $253.00/L $151.80 -466%
Benzotrifluoride $44.60/L $26.76 0.22%
Dichloromethane $44.70/L $26.82
Table 17: Summary of the cost for each substitute on a per L
and the % change in cost involved in substitution.
basis, per 30 g synthesis basis (600 mL),
Where % change in cost is calculated from:
% change in cost = cost of dichloromethane - cost of substitute x 100%
cost of dichloromethane
Methyl cyclopentane will not be included in any substitution investigations, as it is too costly for
consideration.
The cost sensitivity analysis on the replacement of diethyl ether and n-hexane with supercritical CO2
extraction was performed on the basis of a 30g synthesis to facilitate comparison. Table 18 describes the
cost of diethyl ether and n-hexane for a 30 g synthesis.
Volume used in 30g Cost/L Cost
synthesis (mL)
Diethyl ether 6000 mL $64.50/L $387
Hexane 3000 mL $67.40/L $202.20
Total 9000 ML $589.20
Table 18: The cost of diethyl ether and hexane on a per L basis, and per 30 g synthesis basis
Substituting diethyl ether and hexane with the SAS process using the SAS50 system, would require a 2.3
to 2.4 years depending on the solute flowrate used, according to the above analysis. Once the breakeven
point has been reached and the investment in SAS becomes cash flow positive, a cost sensitivity analysis
on SAS versus diethyl ether and hexane extraction (on the basis of a 30 g synthesis) reveals that SAS
process results in an 93 to 97% cost reduction.
Cost for 30 g synthesis % change in cost
SAS extraction (5 mL/min) $43.20 93%
SAS extraction (20 mL/min) $16.20 97%
Dietyl ethr/ Hexane extraction $589.00
Table 19:The cost of SAS extraction (for solute solution flowrates of 5 mlJmin and 20 mULmin, in order
to bracket the entire data set) for a 30 g synthesis basis, compared to that of diethyl
ether/hexane extraction.
I
Where the % change in cost is given by:
% change in cost = Cost of diethyl ether/hexane extraction - Cost of SAS extraction (5 or 20 mL/min)
Cost of diethyl ether/hexane extraction
A cost sensitivity analysis was also performed for the simultaneous substitution of dichloromethane
and replacement of diethyl ether/hexane extraction with the SAS process, to reflect cost savings after the
2.3/2.4 year SAS process breakeven point. This analysis includes two factors (dichloromethane substitute,
SAS process solute solution flowrate) each at two levels (ethyl propionate and isopropyl acetate, and 5
mL/min and 20 mL/min solute solution flowrate), where the levels were chosen to bracket the possible
costs (with one representing the high end of the cost spectrum, and the other representing the low end of
the cost spectrum). Effective comparison of these two factors at two levels requires the creation of a cost
matrix:
Cost Matrix: (hi, hi) isopropyl acetate, SAS 5
(hi, lo) isopropyl acetate, SAS 20
(lo, hi) ethyl propionate, SAS 5
(lo, lo) ethyl propionate, SAS 20
Table 20: Cost Matrix for cost sensitivity analysis of dichloromethane substitution and replacement of
diethyl ether/hexane extraction. For dichloromethane substitution- low: ethyl propionate
($23.64), high: isopropyl acetate ($38.10). For SAS process solute solution flowrate- low: 20
mL/min ($16.20), high: 5 mL/min ($43.20).
Once the cost matrix is created the total cost (for dichloromethane substitution and SAS extraction)
for each bracketing scenario can be calculated and in this way the lowest and highest total costs (and
therefore cost savings) can be identified.
Isopropyl acetate, Isopropyl acetate, Ethyl propionate, Ethyl propionate, Dichloromethane,
SAS extraction SAS extraction SAS extraction SAS extraction diethyl ether/
(5 mL/min) (20 mL/min) (5 mL/min) (20 mL/min) hexane extraction
Substitute cost $38.10 $38.10 $23.10 $23.10 $26.82
Extractant cost $86.40 $32.40 $86.40 $32.40 $589.20
Total cost $124.50 $70.50 $110.04 $56.04 $616.02
% change in cost 79% 89% 82% 91%
Table 21: The costs associated with dichloromethane substitution and SAS extraction for each of the
bracketing scenarios developed in the cost matrix: isopropyl acetate, SAS5; isopropyl acetate,
SAS20, ethyl propionate, SAS5; ethyl propionate, SAS20. As well as the % change in cost as
compared to using dichloromethane and diethyl ether/hexane extraction.
Depending on the dichloromethane substitute and SAS extraction solute solution flowrate chosen, the
percent reduction in cost from instituting these changes ranges from 79 to 91%. Figure 14 shows this
result graphically.
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Figure 14: Percent change (reduction) in cost associated with substituting dichloromethane and
implementing the SAS extraction process (after the 2.4 year break-even point).
While significant cost savings are not realized through substituting dichloromethane with a less toxic
solvent (anywhere from a 43% increase to a 12% decrease in cost are associated with such substitutions),
this substitution is required to avoid the possibility of costly supply chain disruptions in the future. The
disposal cost of dichloromethane as opposed to that of its substitutes was not taken into account for a
couple of reasons: the transportation costs are actually the largest costs associated with disposal and do
not vary with the type of substance disposed (for instance: disposal of a 55 gallon drum of chlorinated
solvents costs $300, while disposal of a 55 gallon drum of nonhalogenated organic solvents costs $150-
200; the transportation cost irrespective of the type of waste ranges from $200-300) and Med Dev does
not generate enough waste for waste disposal costs to be relevant.
The cost savings involved in replacing diethyl ether/hexane extraction with the SAS process are
considerable (ranging from 93 to 97% after breaking even in 2.3 to 2.4 years). The cost analysis was
again performed without consideration of disposal costs for the reasons mentioned above, inclusion of
disposal costs would result in even higher cost savings.
Considering both dichloromethane substitution and the replacement of diethyl ether/hexane
extraction with SAS process (after breaking even in 2.3 to 2.4 years), the cost savings can range from 79-
91% depending on the solute solution flowrate used for the SAS process and the dichloromethane
substitute chosen.
VIII. Conclusion
Med Dev is about to embark on designing its first manufacturing process and is investigating whether
designing for the environment will provide positive returns. The above analysis laid out the laboratory
process currently used and its associated environmental problems, then offered some solutions and their
possible implementation benefits. The larger context suggesting these changes was also developed in
terms of present and future chemicals legislation and strides large pharmaceutical companies are presently
taking to green up and down their supply chains.
On the contextual front, much of the chemical legislation today does not apply to Med Dev since they
are such a small toxic substance user/hazardous waste generator. While the legislation may not directly
apply to Med Dev, Med Dev must be cognizant of it because of the possible implications it could have on
its supply chain (for instance if a particular chemical in Med Dev's synthesis were banned from
production, Med Dev would suffer a serious supply chain disruption). Also future legislation may become
even stricter abandoning de minimus requirements and medicinal product exemptions, directly affecting
Med Dev. Designing a robust process from the beginning is of the utmost importance in the medical
device industry so as to avoid costly revalidation and re-approval from the FDA.
Pharmaceutical companies are becoming increasingly aware of their environmental footprint and are
making strides toward reducing their use of toxic solvents, partially in response to chemical legislation,
but also due to a desire to gain a more positive public perception and to maintain cost competitiveness.
Large pharmaceutical companies have experienced firsthand the cost savings that can be involved in
invoking green chemistry and in an age where generics undercut their ability to gross high profit margins
continually, these cost savings are essential to remaining competitive. Pharmaceutical companies are not
looking within their confines alone to evaluate their environmental performance, rather they are
investigating the environmental performance of their suppliers and their possible acquisitions and making
decisions based on those environmental performances.
Given these contextual drivers, it makes sense that Med Dev would investigate green manufacturing
early. In this thesis, possible green alternatives are offered for investigation and their costs are evaluated.
In the case of dichloromethane substitution with benzotrifluoride, ethyl acetate, isopropyl acetate, ethyl
propionate, or toluene the associated cost savings are not particularly compelling, but the fact that most
major pharmaceuticals are moving away from its use is.
Supercritical carbon dioxide extraction presents significant cost savings (93-97% after allowing 2.3-
2.4 years for capital expenditures to break even) over diethyl ether/hexane extraction, and produce
reproducibly sized particles that will enhance manufacturing control and therefore lead to easier FDA
approval. Overall, instituting both the dichloromethane substitution and the supercritical carbon dioxide
extraction process changes would represent an 80-90% cost savings over doing nothing.
The largest concern that remains is the time required to actually implement these changes, its
estimated that an investigation of the dichloromethane substitutes should take approximately a month, as
should the supercritical carbon dioxide extraction process, these evaluations could be performed
simultaneously, so as to ensure no additional lags. It is still unclear whether a month's wait will
significantly dissuade Med Dev from these valuable process changes, but even if it did, the solutions are
presented here and may be instituted in the future.
Med Dev intends to conduct human clinical trials within the next six months and delaying one month
to make significant process changes could jeopardize this goal. Med Dev is a start-up, and as such there
are two factors that further dissuade it from pursuing process changes that could lead to substantial future
savings: 1.) start-ups have less up-front cash to burn, thus the capital expenditure involved in purchasing
the supercritical extraction equipment may be prohibitive, 2.) Med Dev aims to have an initial public
offering or be acquired within the next year, thus capital expenditures aimed at process improvements and
future cost savings are not immediately salient. Acquisitions and cash burn considerations aside, another
factor dissuading Med Dev from pursuing a more environmentally, economically beneficial process is the
large initial margins associated with their devices. Pharmaceutical companies have long benefitted from
large margins that reward the arduous FDA approval process and as a result have largely ignored process
costs, today this indifference to costs is beginning to change in response to increased competition and
patent expiration that has introduced generics to the market. Med Dev's aspirations towards acquisition,
makes them indifferent toward future cost savings and the possibility of margin erosion due to
competition and patent expiration.
The major incentives to Med Dev adopting the greener manufacturing process presented herein
given their stage in development and their future plans are mostly altruistic: ensuring the health and
wellbeing of their employees and the environment at large, while building a positive environmental
reputation. In addition, implementing environmentally friendly manufacturing processes may attract
possible investors/acquirers, as process changes will be unnecessary to ensure Med Dev is sufficiently in
line with their environmental health and safety regulations.
APPENDIX
A. Licensing and Permitting required for toxic or hazardous substances
Flammable Substance Storage
Flammable substance storage in Massachusetts is covered under 527 Code of Massachusetts
Regulations 14.00 (527 CMR 14.00) ""'. In these regulations a flammable liquid is defined as a liquid
having a flash point below 100 0F and a vapor pressure below 40 psia at 100F. The flash point of a liquid
is the lowest temperature at which a liquid effervesce enough vapor to achieve ignition, though not
sustained combustion. 527 CMR 14.03(1) provides that any entity wishing to keep, store, manufacture, or
sell flammable or combustible liquids or flammable gases must obtain a permit from the head of the fire
department in their locality. The application for the flammable substance storage permit will include the
amounts of flammable substances to be kept and stored and the conditions in which these substances will
be held, and the head of the fire department may require an inspection of the premises prior to issuing a
permit to ensure compliance with 527 CMR 14.00, MGL Chapter 148, and 29 CFR 1910.119 (Process
Safety Management of Highly Hazardous Chemicals). The head of the fire department retains the right to
limit the quantity of flammable substance that can be held at any particular site. The local fire Department
oversees the restrictions in each town/city.
Fines for violation of permitting include:
Permitting Violation Fines' v
$100 -failure to store flammables in prescribed manner
$100 -failure to obtain a permit to store flmmables/combustibles
$100 -failure to obtain a permit for underground storage tanks
Wastewater
Wastewater discharge prohibitions and regulatory requirements are largely decided by local
authorities. Wastewater discharge permitting is required under 314 CMR 17.00. For facilities discharging
under 300 gallons/day, a Low Flow/Low Pollutant General Permit must be filed with the Massachusetts
Water Resources Authority and should include: discharge flow volume (on a daily basis), a sample of
existing discharge, whether a pH adjustment system is in place, a current chemical inventory, and a
chemical management plan. Call 617-305-5950 for the MWRA or The Industrial Coordinator for Toxics
Reduction and Control 617-305-5627 for further information.
Hazardous Waste
Hazardous waste disposal is covered under the 310 CMR 30 regulations in Massachusetts and
Federally by the Resource Conservation and Recovery Act (RCRA) of 1976. Hazardous waste disposal is
becoming more and more costly as fewer hazardous waste disposal sites exist and those that do have
limited capacity. A hazardous waste generator has responsibility, under the Superfund law, for the wastes
they generate from cradle to grave, they must know where their wastes are going and ensure their wastes
are properly handled both during transport and once they reach their final destination. Waste generators
are segmented according to the quantities of hazardous waste they generate:
~Pi
Segmentation of Hazardous Waste Generators"
Segment Quantities Generated
Very Small Quantity Generators (VSQG) 100 kg/month (-25 gallons/month)
Small Quantity Generators (SQG) 1000 kg/month (-250 gallons/month)
Large Quantity Generators (LQG) <1000 kg/month (<-250 gallons/month)
A waste generator must register with the MA DEP and the US EPA as a generator of hazardous
waste, failure to get a registration ID will result in fines of up to $1,000/day, while failure to use an ID on
a manifest could result in additional fines of up to $1,000/day. In addition both hazardous waste
transporters and property/casualty insurers may refuse service to a waste generator who cannot produce a
valid ID. b  The Massachusetts regulations are stricter than the federal regulations, thus compliance
with Massachusetts regulations automatically indicates compliance with federal regulations.
In Massachusetts every shipment of hazardous waste from a SQG or LQG must be accompanied by a
Uniform Hazardous Waste Manifest and be transported by a licensed hauler to a licensed treatment,
storage, or disposal facility (TSDF) or a permitted recycling center. Waste manifests accompany the
shipment and are returned to the waste generator by the TSDF or recycling center where they should be
kept on file for at least 3 years. A small quantity generator, like Med Dev, pays an annual compliance fee
of $525 to the DEP to cover the costs of their services. Wastes are classified as hazardous by 310 CMR
30.133 and for Med Dev Therapeutics, Inc include: ethyl ether (US EPA hazardous waste number U117)
and dichloromethane (US EPA hazardous waste number U080)". The MA DEP's website has a list of
licensed transporters and TSDFs (www.mass.gov/dep), also call the Bureau of Waste Prevention at the
DEP 617-292-5576.
B. Use of RESS and SAS for particle extraction
For RESS
Table 22: Summary of solutes extracted using the RESS process, copied from: Jung, Jennifer, Michel
Perrut, "Review: Particle design using supercritical fluids: Literature and patent survey,"
Journal ofSupercritical Fluids, 20, 179-219 (from pages 183-185)
Table 1
Compounds atomized with the RESS process'
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Table I (continued)
Substrates Supercritical fluidResults and observations Refaences
Flavone and CO.-4-cthanol Polymeric microspheres with tfavone cores Mishima. 1997 1411
XHydroxytlavone +PEG Particle size: 10 um
Griscofulvin CH F Revr-chon. 1995 [331
Hydrogenated palm oil CO. Peirigo. 1998 [47
3Hydroxyflavone-- Eudragit COI+Ethanol The 3-hydroxyflavone is coated thoroughly by Mishima. 2000 [8)
E-100 the polymer
Ibuprofen CO, Capillary nozzle: less than 2 pm Charoenchaitrakool
1999-2000. [51.531
Lazaroid compound U-74389F CO,+EtOH Siewrs. 1993 1281
Lecithin CO2  Particle size: I jim Krukonis. 1984 141
Lidocaine CO: Particle size around 100 nm with spherical shape Frank. 2000 1SSI
Mcvinolin COl Particle size: 0.1-1 4m Mohammed. 1989 1141
CO,+5 wt.% Particle size: 10-50 Pm Larson. 1986 151
MeOH
Nifedipin CO, Particle size: 1-3 ipm Stahl. 1988 [121
PLA +lovastatin CO, Microspheres containing needles of lovastatin Delbenedetti. 1993 122)
PLA +naproxen COU Kim. 1996 [341
PLA +pyrene CO: Debenedetti. 1994 1301
Progaterone CO, Particle size: 2-5 pm Coffey. 1988 1101
Salicylic acid CO, Varying conditions. a wide range of particles Re ,rchon. 1993 126.271
were obtained: particles with diameters from I
to 5 im and length from I to 170 pim
CO, Capillary nozzle: 2-5 pim Sintered nozzle: 1-2 Domingo. 1997 I1W)
jm
Stigmasterol CO, Whisker-like crystals Ohgaki. 1990 1151
Testosterone CO- Particle size: 2-5 pm Coffey. 1988 110l
Theophyllin CO, Needles of length 4-12 tm and diameter 0.9 pim Subra. 1996 1371
a4ocopherol CO2  Particle size: 1-2 Pm Hybertson.1993 1231
Sievers. 1993 128.321
Tropic acid ester CO, Particle size: 5-50 Pm Peiriqo. 1998 1471
- -e
For SAS
Table 23: Summary of solutes extracted using the SAS process, copied from: Jung, Jennifer, Michel
Perrut, "Review: Particle design using supercritical fluids: Literature and patent survey,"
Journal ofSupercritical Fluids, 20, 179-219 (from Table 2, pages 193-197)
Table 2:
Solutes extracted with the SAS process'
Substrates (solntm) Supercritical Process Results and observations References
fluid
Explosites
Cy)lotrimcthylenctri-nitramine (RDX)
(aetone or tcvclohxaeono
ti-HMX (retonej
ti-HMX (acetone)
ft-LMX (g-butyrolactone)
itroguanidine (NMP or DMF)
NMFO (DMF or DMSO or methanol)
Polymers and biopolymers
ALAFF (ester of alginic acid) (DMSO
Lkxtran (DMSO)
Ester of pectinic acid (DMSO)
HPMA (polylhydroxyprop)y
methacrylamide)) (DMSO)
HYAFF 7 (ethyl ester of hyaluronic
acid) (DMSO)
HYAFF 11 (hyaluroanic acid cthyl ester)
(DMSO)
HYAFF II p75 (DMSO)
Inulin (DMSO)
PLA (acetone)
PLA (methylkne chloride)
DL-PLA (n.a.)
DL-PLG (n.a.)
PLGA (awtone)
Pol)ycrylonitrile (DMF)
Pol) aprolaetone (n.a.)
Polylmethacrylated sebacic anhydridc)
(methylene chloride)
CO:. GAS Poduction of void-free particles Particle
ians depending on the conditions: from
2 to I Pm
CO: GAS Particle size: 2-5 am
CO, GAS Particle size: 65 um
COc GAS Particle size: 90 om
CO: GAS Particle size: a few microns Different
Adapes were obtained during the tests
CO. GAS Variety of shapes (sphere. cube.
pherical aggomerate of sizes 0.5-20
am depending upon the conditions
CO,
co:
CO:
CO:
Co:
c,
CO:N:
co..
cO:
CO: +N:
COc
GAS
ASES
GAS
ASES
GAS
ASES
GAS
GAS
ASES
ASES
SEDS
SEDS
GAS
ASE S
SEDS
ASES
Particle size: 0.6 pm
Particle size: 0.1-0.2 4m
Particle size: 0.7 am
Spherical microparticles of diameter
0.1-0.2 Pm
Particle size: 1 pm
Particle size: 0.3-10 .m
Particle size: 0.6 &um
Particle size: 0.8 Mm
Spherical particles with a maximum
dameter of 5 pm
lrittle solid similar to the starting
material
Particle size: I-1t0 am Particle size: 1-2
Am
Particle size: 10 ;am
Particle size: 10 am
Particle size.: 50 nm
Formation of microtibrilles
Particle size: 25-65 pm
A high powred ultraviolet source
dlows photopolymerisation. Particle
size: 1-5 Pm
Gallagher. !992 19.101
Cai. 1997 1241
Farter-Barth. 1999 [56J
Fl ter-Barth. 1999 1561
Gallagher. 1989 161
tim. 1996 138
Pallado. 1996 [23[
RePsrchon. 1999 1541
Pallado. 1996 123j
Reverchon. 1999 (611
Pallado. 1996 1231
ltmedeti. 1993 11II Resrchon. 1999
Pallado. 1996 123
Pallado. 1996 1231
Reverchon. 1999 (54.611
Chou. 1997 1251
Blich. 1993 113 Rermchon. 1999 161)
Ghaderi. 1999 [661
Ghaderi. 1999 1686
Dillow. 1997 261
.bhnston. 1994 (191
Ghaderi. 1999 1681
Owens. 1999 167;
Table 2 (continued)
Substrates Isolvent) Supercritical Process Results and observations References
fluid
Polystyrene (toluene)
Polystyrenc !toluenc
CO ASES
CO, SEDS
Inorbgnic and organic materials: coloring matters. catalysts. superconductor..
Ammonium Chloride (DMSO) CO: GAS
Barium Chloride (DMSO) CO. GAS
Ikonze Red (ethanol)
Bronze Red (acetone)
Buckminster-fullcrene (toluene)
Cobatous nitrate (acetone) CO:
Epoxy powder factone or methyl ethyl CO:
ketone)
Hydroquinone (acetone) CO
Nickel Chloride hexahydrate (absolute CO:
ethanol)
Phenanthrene (toluene) CO,
Red Lake C pigment Pigment Yellow I CO:
Mgment Blue 15 (a&ctone)
Samarium acetate (DMSO) CO:
Samarium acetate (water+methanol) CO.
Silver nitrate (methanol) CO:
Superconductor precursors CO:
Yttrium acetate (DMSO) CO:
Zinc acetate (DMSO) CO:
Pharnmaceical compoundr
Acetaminophen (ethanol) CO:
Albumin (water) CO:-
7-aminoerphalo-sporaric acid (acetone and CO:
water)
Amoxicilin (NMP) CO:
Antibody Fab fragment (water) CO-,
Antibody Fv fragment (water) CO.-
Ascorbic acid (ethanol) CO,
Table 2 (continued)
CO ASES
CO, ASES
CO: ASES
Particle size: 0. 1-20 pm
Particle size: 0.5 pm
Particle size: 1-5 pm
Dixon. 1993 1141
tlanna. '998 1361
Yeo. 2000 1841
Particle size: 7-9 pm with cubic shape or Yeo. 2000 1841
needlelike crystals depending on the
conditions
Spheres of diameter between I and 10 pnHong. 2000 176)
depending on experimental conditions
Spheres or needles of diameter between 3 Hong. 2000 1761
and 15 pm depending on the conditions
Particle size: 100-300 nm Chattopadhyay. 2000 1711
SEDS Frcc-flowing pink powder Hanna. 1994 [181
ASES Hithout surfactant: agglomerates with Heater. 1998 1371
pluronic R-17: separated partiles with
uniform spherical morphology
GAS and ASES GAS: aggkimerates of size 500 pm ASES: Wubbolts. 1997 1321
nedle and prismatic shaped particles of
size 50-100 pm
SEDS
GAS
GAS
ASES
SEDS
SEDS
ASES
ASES
ASES
SEDS
4-Ethanol SEDS
GAS
+ahanol
+.hanol
ASES
SEDS
SEDS
ASES
Very tir free-flowing powder
Particle size: 160-540 pm
Particle size: down to 0.6 pm
Particle size: 0.1-0.3 Opm
Particle size: 0.2 pm
Particle sire: 0.3 pm
Ballons formed by submicronic elements
Particle size: 0.08-0.13 Pm
Particle size: 4 pm
Particle size: 50-500 nm
n.a.
Particle size: 0.2-0.6 pm
Activity of proceased antibody: 49~i
Activity of processed antibody- 3%
Particle size: 1-10 pm
Hanna. 1994 118l
lkrends. 19941161
Gao. 1997 1271
Re vrchon. 1997 129.441
Hanna. 1998 1361
Hanna. 1998 1361
Reverhon. 1998 1421
Reverchon, 1997 129.431 Muhrer. 2000
1781
Reverchon. 1997 130.631
Glbert, 2000 171S)
Bustami. 2000 1701
Liang. 2000 1771
Reverchon. 1999 157.641
Sloan. 1999 151
Sloan. 1999 151
Weber. 1999 15S)
b I
Substrates (sovrnt) Supercritical Process Results and observations References
fluid
carotene (ethyl actate) CO, GAS Particle size: platchlt morphology of 2-10 Cocero. 2000 172,1
Catalase (ethanol-water 9010)
Substrates (sohvent)
Chloramphenicol (ethanol)
Cuindomethacin), (DMFh) (DMF)
pH-lIA (methanol)
-ydrocortisone acetate (DMF)
Insulin (ethanol-water 90: 10)
hsulin (water)
Insulin (DMSO or DMF)
Insulin (Methanol)
Insulin (Ethyl acetate)
Insulin (Ethanol)
Insulin (water)
-lactamase (water)
Lactosc (water)
Lecithin (ethanol or hexane)
Lobenzarit disodiuman (water)
Lysozym (water)
Lysozyr (DMSO)
Lysorym (DMSO)
Lysoryzc (DMSO)
Lysozyme (DMSO)
Lysorzym (Ethanol)
Lysoryme (Methanol)
Lysoryme (Water)
Maltose (water)
Mdfenamic acid (methanol or ethanol or
acetone)
Table 2: (continued)
co,
Supercritical
fluid
CO:
CO,
CO,
CO,
CoNHCO,+ Ethanol
CO: andComethanlC02co,CO,+cthanol
CO and
methanol
CO,
CO + Ethanol
CO+ethanol
ASES
Process
ASES
GAS
GAS ASES
ASES
ASES
SEDS
ASES
GAS
GAS
GAS
GAS
SEDS
SEDS
ASES
ASES
SEDS
CO, GAS
CO:+ DMF GAS
(30% Vol.)
CO:+ Ethanol GAS
(3C% vol.)
CO+ acetic acidGAS
(8%f vol.
CO:1.water GAS
CO: GAS
NH, GAS
CO:+ absolute SEDS
ethanol
C: ASES
Om size
Particle size: i pm Lkbenedetti. 1992 (8)
Results and observations References
Particle size: 1-10 um %%ber. 1999 (551
Slow expansion: rhombic crystals of 50 Warwick. 2000 [83)
pm size Fast expansion: crystals of 20 am
ize
GAS: Particle size: 1-2 isn ASES: 0.1-1.0 lhiering. 1996 49)
pm
Particle size: 5 pm
Particle size: I pm
Particle size: 50-500 nm
Particle size 1j51: <4 pm Particle size
I80.81.82: 1.4-1.8 pm
Particle size: 0.2-0.7 pm
Particle size: 0.3-0.7 pm
Particle size: 0.05-0.3 pm
Particle size: 0.2-0.3 pm
Particle morphology depends on the
nozzle Particle size: 3.0-10.5 pm
Particle size: 0.2-0.6 pm
Particle size 1461: 0.78 pm Activity of
procssed enzyme: 99"% Particle size 701:
500 nm Particle size 75): 0.5-5 am
Particle size: 0.5-0.2 pm
Particle size: 0.1 pam
Particle size: 0.02-0.04 Apm
Schmitt. 1995 1!22'
fkbcncdctti. 1992 81
Bustami, 2000 170)
Yeo. 1993 115) Thiering. 2000 (80. 1.821
Thiering. 2000 I80.81.821
Thicring. 2000 180.81.82)
Thiering. 2000 (80.81.82)
Thicring. 2000 (80.81.821
Hanna. 1994 [I8)
Hanna. 1995 121I Palakodaty. 1996 1401
VHeber. 1999 (591
D. Amaro-Gonzalcz. 2000 169)
Stoan, 1998 146) lustami. 2000 70t
Gilbert. 2000 (75)
Thiering. 2000 [80.81.821
Thiering. 2000 160.81.821
Thiceing. 2000 [80.81.82)
Particle size: 0.05 widthx 0.25 length Thiering. 2000 180.81.82)
Particle size: 0.05-0.07
Particle size: 0.01-0.05 pam
Particle size: 0.05-0.2 pm
Result: free-flowing white powder
Particle size: M0-50 pm
Thiering. 2000 (80.81.82)
Thiering. 2000 .80.81.82)
Thiering. 2000 [80.81.82)
Hanna. 1995 [21)
Bustami. 1999 1661
-~ - -~
Substrates (solvent Supercritical Process Results and observations References
fluid
Methylprednisolone (tetrahydrofuran) CO= or ethane ASES Particle size: 5 pm Schmitt, 1995 [221 Muhrcr, 2000 [781
Myoglobin (DMSO) COc GAS Particle size: 0.0340.4 am Thiering. 2000 180.81.82
Myoglobin (Methanol) CO, GAS Particle size: 0.05-4.3 pm Thiering. 2000 [80.81.821
Naproxen (acetone) CO, ASES Needlm-like crystals with diameter I am Chou. 1997 1251
and length I mm
Nicotinic acid (absolute ethanol) COz SEDS Particle size: 0..4-075 pm Hanna. 1998 I361
Paracetamol (ethanol) CO ASES Particle size: 1-10 gm Weber. 1999 [551
Phospholipids (chloroform or ethanol) CO: ASES Spherical particles of size: 1-40 uam Magnan. 1999 153.601
Plasmid DNA pSVb with no protectant COC:.-hanol SEDS Activity of processed plasmids: 10W Sloan. 1999 [586
(water)
Plasmid DNA pSVb with protectant CO-..hanol SEDS Activity of processed plasmids: 7 5/ Sloan. 1999 [58S
(water)
Prednisolone acetate (acetone) CO ASES Particle size: I um Anderson. 1996 [331
RhDNase (water) CO,-ethanol SEDS Particle size: 50-500 nm B&stami. 2000 1701
Salbutamal(methanol--acetone) CO, SEDS Particle size: 0.5 pm Hanna. 1998136 i
Salmeterol xinafoate (methanol or acetone) CO: ASES Particle size: 1-10 pm Hanna. 1994 (18l Hanna. 1998 (35)
Salmeterol xinafoate (acetone or methanol) CO, SEDS With acetone platelet particles with Hanna. 199 [136[
methanol: needles-like particles
Sodium cromoglicatl (methanol) COz ASES Particle size: 0.1-20 gm Jaarmo. 1997 [2)
Sucrose (water) COC, absolute SEDS Result: free-flowing white powder Hanna. 1995 [21i
ethanol
Tetracycline (NMPs' COc ASES Particle size: 0.6-0.6 m Reverchon. 1999 157.64J. 2000 [79j
Trehalose (water) COC- absolute SEDS Result: free-flowing white powder Hanna. 1995 1211
ethanol
Trypsin (HCI ImM) CO+-ethanol SEDS Particles size: 1.53 pm Activity of Sloan. 1998 [46[
processed enzyme: 36%
Urea (ethanol) COC ASES Particle size: 1-10 pm Wber. 1999 [S55
M.icrocomponries
Calcitonin+HYAFF (DMSO) CO, GAS Particle size: 0.5-1 pm Pallado. 1996 [23
Chimotrypsin-AOT+ LA (methylene CO: ASES Particle size: 1-2 am Elvassore. 2000 [731
chloride)
Chloramphenicol and urea lethanol' CO: GAS Weber. 19968 501
Copper-. Barium. and Yttrium acetate COl ASES Composite particles of 50-150 nm with a Weber. 1999 [55)
(ethanol) unique homogeneous distribution of each
of the elements
GMCSF+ HYAFF (DMSO) CO2  GAS Particle size: 0.5-1 gm Pallado. 19%6 j23[
p-HBA (methanol)+PLGA (aeetone) CO: SEDS Crystals of p-HBA coated with a layer of Sce Tu. 1998 [461
PLGA microspheres
pHBA (methanol)+PLA (methylene CO: SEDS Fibrous network of drug and polymer Sze Tu. 19968 ([4
chloride) mixture
Table 2 (continued)
Substrates (solvent) Supercritical Process Results and observations References
fluid
Hydrocortisone + CO +N: SEDS Particle size: 10-60 pm Ghaderi. 1999 [68]
Poly(DL-lactide-co-lycolide):copolymer
composition 50:50 (n.a.)
Insulin+ HYAFF (DMSO) CO' GAS Particle size: 0.4 pm Pallado, 1996 [23]
Insulin-lauric acid conjugate+PLA CO: ASES Particle size: 1-5 pm Elvassore, 2000 [73]
(methylene chloride)
Insulin+ PLA (methylene CO: ASES Particle size: 1-5 pm Elvassore, 2000 [731
chloride+ DMSO 590%)
L)sozyme+PLA (methylene COl ASES Particle size:1-2 pm Elvassore, 2000 [73]
chloride+ DMSO 5rVo)
Naproxen+PLA (acetone) COl ASES Particle size: 5 pm Chou, 1997 [25]
Paracetamol and ascorbic acid (ethanol) CO: GAS By variation of the composition, the Weber, 1998 [50]
product changed from needle-like
crystals (10 pm) to large tubes (length
30-100 pm, diameter 2 pm) covered
with prismatic crystals (<I pm)
PLA+clonidine HCI (dichloromethane) CO, ASES Hollow spheres of diameter; 100 pm Schwarz Pharma. 1987 [4]
PLA+hyoscine (butylbromide) CO. ASES Particle size <20 pm Bleich, 1994 [17]
Salmeterol CO: SEDS Fine white powder Hanna, 1994 [18]
xinartfoate + hydrox proprop)lcellulose
(acetone)
e
C. Sample Calculation for Dichloromethane Consumption in Europe
DCM paintstripping (tons)
revenue DCM paint stripping ($S750on)
total DCM (tons)
revenue for total DCM ($750/to n)
revenue for total DCM ($750/ton)-revenue DCM paint stripping ($750/tDn)
10% of(revenue for tota DCM ($750/ton)-revenue DC M paint stripping ($750/ton))
revenue for total DCM($750/ton)-revenue DCM paints tripping ($750/ton)-10% of'"
50% of (revenue for totd DCM ($750/ton) -reven ue DCM paint stripp hg ($750/tDn))
revenue for total DCM ($750/ton)-revenue DCM paints tripping ($750/ton)-50% of'"
$750/ton less 10%
$750/ton less 50%
DCM pharma (tons)
revenue DCM pharma ($675/ n)
reven ue DCM pharma ($375/o n)
(revenue for total DCM($750/ton)-reven ue DCM pint stripp h g ($750/n)-10% of" "/revenue for ltal DCM ($750/ton))*100
13000
9750000 DCM paint stripping (tons) x ($750/ton)
110000
82500000 total DCM (tons) x ($750/ton)
72750000
7275000
65475000
36375000
36375000
675
375
50000
33750000 DCM pharma (tons) x ($675/ton)
18750000 DC Mph arma (tons) X ($375/ton)
20.63636364
D. Synthesis Costs
For the original process:
The following calculations are based on the assumptions:
03 mL of hydrogelpatient
PEG-co-poly(lactic acid) diacrylate30% (wt/vol) in PBS
Market (contusion patients and off label): 10k in the US, 30k in Europe (say 40% of this overall market is captured: 16k)
1440 g of PEG-co-poly(lactic acid) diacrylate
Ring opening polymerization of lactide
Original process MW (g/mol)
PEG 6k 6009.09
d,l-lactide 146.14
dichloromethane 84.93
diethyl ether 74.12
stannous octoate 405.1
PEG- co-poly(lactic acid) 6729.71
total
for synthesis of 1,440 g (48 times the 30 g synthesis)
Acrylation
Original process MW (g/mol)
PEG- co-poly(lactic acid) 6729.71
dichloromethane 84.93
triethylamine 149.188
acryloyl chloride 90.5
diethyl ether 74.12
hexane 86.18
PEG-co-poly(lactic acid) diacrylate 6821.8
Triethylamine hydrochloride 185.65
total
for synthesis of 1,440 g (48 times the 30 g synthesis)
thus the overall cost for the synthesis:
For benzotrifluoride substitution:
amount used
30g
3.60 g
300 mL
3000 mL
0.0150 g
33.2 g
amount used
30g
300 mL
131 mL
1.77 g
3000 mL
3000 mL
30.4 g
1.66 g
price/unit
$54.10/kg
$19.10/10og
$44.70/L
$64.50/L
$19.10/100g
cost ($)
1623
0.6876
13.41
193.5
0.002865
amount used/year
1440 g
172.8 g
14.4 L
144 L
0.72g
209.223465
10042.7263
price/unit
$44.70/L
$61.90/L
$38.80/5g
$64.50/L
$67.40/L
cost ($)
2092235
13.41
0.081089
13.7352
193.5
202.2
amount used/year
1440 g
14.4 L
62.88 mL
84.96 g
144 L
144 L
632.149789
S30343.1899
$30,343.19
Ring opening polymerization of lactide
Benzotrifluoride substitution MW (glmol)
PEG 6k 6009.09
d,l-lactide 146.14
benzotrifluoride 146.11
ethyl acetate 88.105
stannous octoate 405.1
PEG-co-poly(lactic acid) 6729.71
tota I
for synthesis of 1,440 g (48 timesthe 30 g synthesis)
Acrylation
Benzotrifluoride substitution
PEG-co-poly(lactic acid)
benzotrifluoride
triethylamine
acryloyl chloride
ethyl acetate
heptane
PEG-co-poly(lactic acid) diacrylate
Triethylamine hydrochloride
MW(g/mol)
6729.71
146.11
149.188
90.5
88.105
100.21
6821.8
185.65
amount used
30g
3.60 g
300 mL
3000 mL
0.0150 g
332 g
amount used
30g
300 mL
1.31 mL
1.77 g
3000 mL
3000 mL
30.4 g
1.66 g
price/unit
$54.10/kg
$19.10/100g
$44.60/L
$55.70/L
$19.10/100 g
cost ($)
1.623
0.6876
13.38
167.1
0.002865
amount used/year
1440 g
172.8 g
14.4 L
144 L
0.72g
182.793465
8774.08632
price/unit
$44.60/L
$61.90/L
$38.80/5g
$55.70/L
$56.70/L
cost ($)
209.2235
13.38
0.081089
13.7352
167.1
170.1
amount used/year
1440 g
14.4 L
62.88 mL
84.96 g
144 L
144 L
tota I
for synthesis of 1,440 g (48 timesthe 30 g synthesis)
E. SAS process Economics
assumption: 30 g synthesis
Solute solution
Flowrate
(mL/min)
1
5
10
15
20
time required
for 3000mL
solute solution
(min)
3000
600
300
200
150
Amountof numberof
total time (with
additional 120
minutes wash) (min)
3120
720
420
320
270
C02 flowrate
(g/min)
50
50
50
50
50
C02
required
(g)
156000
36000
21000
16000
bottles of
C02
required C02 Cost
7.8 187.2
1.8 43.2
1.05 25.2
0.8 19.2
13500 0.675
C02: 20000 g/bottle
$24/bottle
16.2
Cost of SAS system: -$65,000.
573.619789
27533.7499
cost of
cost of supercritical
supercritical C02 C02 @ solute
Amount of cost of diethyl @ solute flow of flow of 20
polymer ether/hexane 5 mL/min ml/min
30 589.2 65043.2 65016.2
60 1178.4 65086.4 65032.4
90 1767.6 65129.6 65048.6
120 2356.8 65172.8 65064.8
150 2946 65216 65081
180 3535.2 65259.2 65097.2
210 4124.4 65302.4 65113.4
These calculations were performed until sufficiently many points were calculated to allow a break-even
point to emerge, then the results were plotted to help facilitate identification of the break-even point.
break even point for: g g/year years to break even
Supercritical C02 @ solute flow 5 mL/min 3570 1460 2.445205479
supercritical C02 @ solute flow 20 mL/min 3390 1460 2.321917808
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